How many Ibrutinib clinical trials are there?

352 Ibrutinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 36 are actively recruiting participants. 152 are marked completed.

Are Ibrutinib clinical trials recruiting in 2026?

Yes — 36 Ibrutinib trials are actively recruiting in 2026, with 557 U.S. sites across 44 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Ibrutinib being studied for?

Ibrutinib is being studied for Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Recurrent Small Lymphocytic Lymphoma and 407 more. The trials are grouped by indication on this page.

What phase is Ibrutinib in?

Ibrutinib clinical trials span 4 Phase 4, 53 Phase 3, 148 Phase 2, 75 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Ibrutinib clinical trials?

The lead sponsor across the most Ibrutinib trials is Janssen Research & Development, LLC, with 139 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Ibrutinib Clinical Trials (2026): 352 Studies for Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma

Creator: Hipa.ai Research
Published: 2026-06-02T16:41:11.816Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 16, 2026.

352 Ibrutinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 177 indications (including Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma) and 73,619 total planned enrollment. 53 Phase 3 Ibrutinib trials and 148 Phase 2, 4 Phase 4 are listed. 39 Ibrutinib clinical trials are actively recruiting at 557 U.S. sites across 44 states. Most recent activity: NCT07474961 (Dec 2036).

Where to Participate: All Ibrutinib Trial Sites in the U.S. (557 sites across 44 states)

Every actively recruiting Ibrutinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Alabama Neurology Associates PC	Birmingham35209	NCT07225504	Map
AL	Allervie Clinical Research	Birmingham35209	NCT06868212	Map
AL	Cahaba Derm and skin hlth ctr 27	Birmingham35244	NCT06868212	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT03331198	Map
AL	University of Alabama Birmingham	Birmingham35294	NCT03331198	Map
AL	USA Mitchell Cancer Institute ( Site 0014)	Mobile36604	NCT06136559	Map
AZ	Banner MD Anderson Cancer Center	Gilbert85234	NCT03331198	Map
AZ	Banner MD Anderson Cancer Center	Gilbert85234	NCT03331198	Map
AZ	Banner MD Anderson Cancer Center ( Site 0059)	Gilbert85234	NCT06136559	Map
AZ	Research Solutions of Arizona	Litchfield Park85340	NCT06868212	Map
AZ	Peak Dermatology	Payson85541	NCT06868212	Map
AZ	Avacare Center for Dermatology	Phoenix85044	NCT06868212	Map
AZ	AZ Integrated Neuro and Spine	Phoenix85037	NCT07225504	Map
AZ	Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051)	Phoenix85006	NCT06136559	Map
AZ	Neuromuscular Research Center	Phoenix85013	NCT06744920	Map
AZ	Premier Allergy Asthma And Immunology	Phoenix85032	NCT06868212	Map
AZ	St. Joseph's Hospital and Medical Center	Phoenix85013	NCT03328078	Map
AZ	Honor Health Research Institute	Scottsdale85258	NCT06744920	Map
AZ	Orso Health	Scottsdale85254	NCT06868212	Map
AZ	Perseverance Research Center	Scottsdale85253	NCT06846281	Map
AZ	Banner University Medical Center - Tucson	Tucson85719	NCT04840602	Map
AZ	Center for Neurosciences	Tucson85718	NCT07225504	Map
AZ	University of Arizona Cancer Center-North Campus	Tucson85719	NCT04840602	Map
AR	Clin Trial Inst of Northwest AR	Fayetteville72703	NCT06868212	Map
AR	Acuro Research Inc	Little Rock72205	NCT06868212	Map
CA	Pacific Cancer Medical Center, Inc	Anaheim92801	NCT05254743	Map
CA	Alta Bates Summit Medical Center ( Site 0004)	Berkeley94704	NCT06136559	Map
CA	The Oncology Institute Clinical Research	Cerritos90703	NCT05963074	Map
CA	TOI Clinical Research	Cerritos90703	NCT05254743	Map
CA	City of Hope	Duarte91010	NCT03328078	Map
CA	City of Hope	Duarte91010	NCT03331198	Map
CA	City Of Hope	Duarte91010	NCT03331198	Map
CA	First OC Dermatology	Fountain Valley92708	NCT06868212	Map
CA	Ctr for Dermatology Clinical Res	Fremont95438	NCT06868212	Map
CA	Fullerton Neuro and Headache Ctr	Fullerton92835	NCT06744920	Map
CA	Fullerton Neuro and Headache Ctr	Fullerton92835	NCT07225504	Map
CA	Allergy and Asthma Specialists Group	Huntington Beach92647	NCT06868212	Map
CA	University of California Irvine	Irvine92697	NCT06846281	Map
CA	Moores Cancer Center ( Site 0003)	La Jolla92093-0698	NCT06136559	Map
CA	UC San Diego Moores Cancer Center	La Jolla92093	NCT03331198	Map
CA	University Of California San Diego Moores Cancer Center	La Jolla92093	NCT03331198	Map
CA	Ark Clinical Research	Long Beach90815	NCT06868212	Map
CA	Orso Health	Long Beach90808	NCT06868212	Map
CA	Cancer and Blood Specialty Clinic	Los Alamitos90720	NCT05963074	Map
CA	California Allergy and Asthma Medical Group	Los Angeles90025	NCT06868212	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT06649812	Map
CA	Dermatology Research Associates	Los Angeles90045	NCT06868212	Map
CA	University of California, Los Angeles	Los Angeles90095	NCT03331198	Map
CA	University Of Southern California	Los Angeles90033	NCT06744920	Map
CA	One Of A Kind Clinical Research	Napa94558	NCT06868212	Map
CA	St. Joseph Hospital Center for Cancer Prevention and Treatment	Orange92868	NCT01804686	Map
CA	Univ Cali Irvine ALS Neuromuscular	Orange92868	NCT06744920	Map
CA	Stanford School of Medicine-Cancer Clinical Trials Office	Palo Alto94305	NCT05254743	Map
CA	Care Access - South Pasadena ( Site 0070)	Pasadena91105	NCT06136559	Map
CA	Empire Clinical Research	Pomona91767	NCT06868212	Map
CA	Allergy and Asthma Consultants	Redwood City94063	NCT06868212	Map
CA	Norcal Clinical Research	Rocklin95765	NCT06868212	Map
CA	Peninsula Research Associates	Rolling Hills Estates90274	NCT06868212	Map
CA	California Pacific Medical Center	Sacramento94115	NCT06744920	Map
CA	Integrative Skin Science and Res	Sacramento95815	NCT06868212	Map
CA	UC Davis Neuromuscular Research Center	Sacramento95817	NCT06868212	Map
CA	Therapeutics Clinical Research	San Diego92123	NCT06868212	Map
CA	San Francisco VA Medical Center, San Francisco, CA	San Francisco94121-1563	NCT06520098	Map
CA	University of California, San Francisco	San Francisco94143	NCT03331198	Map
CA	SLO Oncology and Hematology Health Center	San Luis Obispo93401	NCT05963074	Map
CA	Dermatology Institute and Skin Care	Santa Monica90404	NCT06868212	Map
CA	Providence St. John's Health Center	Santa Monica90404	NCT03328078	Map
CA	Providence Medical Foundation	Santa Rosa95403	NCT05963074	Map
CA	Integrated Research of Inland Inc	Upland91786	NCT06868212	Map
CA	Allergy and Asthma Clin Res Inc	Walnut Creek94598	NCT06868212	Map
CA	Regina Berkovich MD PhD Inc	West Hollywood90048	NCT07225504	Map
CA	PIH Health Hospital	Whittier90602	NCT05963074	Map
CO	University of Colorado Hospital - Aurora	Aurora80045	NCT06868212	Map
CO	Asthma and Allergy Associates P C	Colorado Springs80907	NCT06868212	Map
CO	Colorado ENT and Allergy	Colorado Springs80909	NCT06868212	Map
CO	Skylight Health Res Inc Color Spr	Colorado Springs80917	NCT06868212	Map
CO	Colorado Blood Cancer Institute	Denver80218	NCT03331198	Map
CO	Saint Joseph Hospital ( Site 0026)	Denver80218	NCT06136559	Map
CO	Lutheran Medical Center ( Site 0027)	Golden80401	NCT06136559	Map
CO	Grand Valley Oncology	Grand Junction81505	NCT05963074	Map
CO	Intermountain Health St. Mary's Regional Hospital ( Site 0025)	Grand Junction81501	NCT06136559	Map
CT	Smilow Cancer Hospital-Derby Care Center	Derby06418	NCT06649812	Map
CT	UCONN Health Dermatology	Farmington06030-2840	NCT06868212	Map
CT	Smilow Cancer Hospital Care Center - Guilford	Guilford06437	NCT06649812	Map
CT	Yale University	New Haven06520	NCT06649812	Map
CT	Yale University School of Medicine /ID# 242089	New Haven06510	NCT05283720	Map
CT	Eastern CT Hematology & Oncology Associates ( Site 0033)	Norwich06360	NCT06136559	Map
DE	Christiana Care Health Service /ID# 242301	Newark19713	NCT05283720	Map
DC	Georgetown University Hospital	Washington D.C.20007	NCT07225504	Map
DC	Georgetown University Medical Center	Washington D.C.20007	NCT03331198	Map
DC	Howard University Hospital Division of Geriatrics	Washington D.C.20059	NCT06868212	Map
DC	Medstar Washington Hosp Ctr	Washington D.C.20010	NCT07225504	Map
DC	Medstar Washington Hospital Center	Washington D.C.20010-2975	NCT06744920	Map
DC	Medstar Washington Hospital Center	Washington D.C.20010-2975	NCT06846281	Map
FL	Neurology of Central FL Res Ctr	Altamonte Springs32714	NCT06846281	Map
FL	Neurology of Central FL Res Ctr	Altamonte Springs32714	NCT07225504	Map
FL	Florida Ctr Allergy Asthma Research	Aventura33180	NCT06868212	Map
FL	Florida Ctr Allergy Asthma Research	Aventura33180	NCT06868212	Map
FL	SFM Clinical Research LLC	Boca Raton33487	NCT06744920	Map
FL	Skin Care Research Inc	Boca Raton33486	NCT06868212	Map
FL	Clermont Oncology Center ( Site 0046)	Clermont34711	NCT06136559	Map
FL	UM Sylvester Comprehensive Cancer Center at Coral Gables	Coral Gables33146	NCT04840602	Map
FL	UM Sylvester Comprehensive Cancer Center at Coral Springs	Coral Springs33065	NCT04840602	Map
FL	UM Sylvester Comprehensive Cancer Center at Deerfield Beach	Deerfield Beach33442	NCT04840602	Map
FL	Omnicure Clinical Research	Doral33172	NCT06868212	Map
FL	UM Sylvester Comprehensive Cancer Center at Doral	Doral33166	NCT04840602	Map
FL	FXM Clinical Research Ft Laud	Fort Lauderdale33308	NCT06868212	Map
FL	Florida Cancer Specialists	Fort Myers33916-2233	NCT05254743	Map
FL	Florida Cancer Specialists - South ( Site 7001)	Fort Myers33901	NCT06136559	Map
FL	UF Health Cancer Center	Gainesville32610	NCT07225504	Map
FL	University of Florida	Gainesville32610	NCT06846281	Map
FL	Skin Care Research LLC	Hollywood33021	NCT06868212	Map
FL	UM Sylvester Comprehensive Cancer Center at Hollywood	Hollywood33021	NCT04840602	Map
FL	Homestead Assoc In Research Inc	Homestead33033	NCT06744920	Map
FL	Homestead Assoc In Research Inc	Homestead33033	NCT07225504	Map
FL	Jacksonville Center for Clinical Research	Jacksonville32216	NCT06868212	Map
FL	Mayo Clinic	Jacksonville32224	NCT03328078	Map
FL	Mayo Clinic	Jacksonville32224	NCT03331198	Map
FL	Mayo Clinic - Jacksonville	Jacksonville32224	NCT03331198	Map
FL	Mayo Clinic in Florida	Jacksonville32224-9980	NCT04840602	Map
FL	Neurology Associates PA	Maitland32751	NCT06744920	Map
FL	Neurology Associates PA	Maitland32751	NCT06846281	Map
FL	Neurology Associates PA	Maitland32751	NCT07225504	Map
FL	FXM Clinical Res Miami LLC	Miami33175	NCT06868212	Map
FL	Miami Dade Medical Research	Miami33176	NCT06868212	Map
FL	Miami NS Ins Baptist Health S FL	Miami33176	NCT07225504	Map
FL	UM Sylvester Comprehensive Cancer Center at Kendall	Miami33176	NCT04840602	Map
FL	University of Miami Miller School of Medicine-Sylvester Cancer Center	Miami33136	NCT04840602	Map
FL	University of MiamiHealth System	Miami33125	NCT06868212	Map
FL	Mount Sinai Medical Center Campus	Miami Beach33140-2948	NCT05963074	Map
FL	FXM Clin Res Miramar LLC	Miramar33027	NCT06868212	Map
FL	Aqualane Clinical Research	Naples34105	NCT06846281	Map
FL	Aqualane Clinical Research	Naples34105	NCT07225504	Map
FL	University of Miami Sylvester Comprehensive Cancer Center at Sole Mia	North Miami33181	NCT04840602	Map
FL	The Oncology Institute	North Miami Beach33169	NCT05963074	Map
FL	Ziaderm Research LLC	North Miami Beach33162	NCT06865651	Map
FL	Ziaderm Research LLC	North Miami Beach33162	NCT06868212	Map
FL	Mid Florida Hematology Oncology	Orange32763	NCT05963074	Map
FL	Advent Health Orlando	Orlando32803	NCT06846281	Map
FL	AdventHealth	Orlando32804	NCT06744920	Map
FL	Comprehensive Neurology Clinic	Orlando32825	NCT07225504	Map
FL	Neurological Services of Orlando PA	Orlando32806	NCT06744920	Map
FL	Orlando Health Clinical Trials	Orlando32806	NCT06846281	Map
FL	Orlando Health Clinical Trials	Orlando32806	NCT07225504	Map
FL	Neurology Associates of Ormond Beach	Ormond Beach32174	NCT07225504	Map
FL	AllerVie Health	Panama32405	NCT06868212	Map
FL	UM Sylvester Comprehensive Cancer Center at Plantation	Plantation33324	NCT04840602	Map
FL	Cancer Specialists of North Florida -St Augustine	Saint Augustine32086	NCT05254743	Map
FL	Sarasota Clinical Research	Sarasota34233	NCT06868212	Map
FL	Lenus Research and Med Group LLC	Sweetwater33172	NCT06868212	Map
FL	Tallahassee Neurological Clinic	Tallahassee32308	NCT06846281	Map
FL	Asthma Allergy Immunology Clin Res	Tampa33613	NCT06868212	Map
FL	Axiom Brain Health	Tampa33609	NCT07225504	Map
FL	Olympian Clinical Research	Tampa33609	NCT06868212	Map
FL	Tampa General Hospital /ID# 246748	Tampa33606	NCT05283720	Map
FL	University Of South Florida	Tampa33612	NCT06846281	Map
FL	Vero Beach Neurology	Vero Beach32960	NCT06846281	Map
FL	Florida Cancer Specialists - East ( Site 7002)	West Palm Beach33401	NCT06136559	Map
FL	Florida Cancer Specialists East	West Palm Beach33401	NCT05254743	Map
FL	Conquest Research	Winter Park32789	NCT06868212	Map
GA	The Blood and Marrow Transplant Group of Georgia (BMTGA)	Atlanta30342	NCT03331198	Map
GA	Augusta University, Georgia Cancer Center	Augusta30912	NCT05106296	Map
GA	AllerVie Clin Res Columbus GA	Columbus31904	NCT06868212	Map
GA	Cleaver Medical Group	Cumming30040	NCT06868212	Map
GA	Southeast Dermatology Specialists	Douglasville30135	NCT06868212	Map
GA	Aeroallergy Research Laboratories	Savannah31406	NCT06868212	Map
GA	Joi Life Wellness Group LLC	Smyrna30080	NCT07225504	Map
HI	Hawaii Pacific Neuroscience LLC	Honolulu96817	NCT07225504	Map
ID	Boise VA Medical Center	Boise83702	NCT05963074	Map
ID	The Allergy Group-Meridian Clinic	Meridian83642	NCT06868212	Map
ID	Saint Alphonsus Cancer Care Center-Nampa	Nampa83687	NCT04840602	Map
IL	Centralia Oncology Clinic	Centralia62801	NCT04840602	Map
IL	Northwestern Memorial Hospital	Chicago60611	NCT03328078	Map
IL	Northwestern Memorial Hospital	Chicago60611	NCT03331198	Map
IL	Northwestern Memorial Hospital	Chicago60611	NCT07225504	Map
IL	Northwestern University	Chicago60611	NCT03331198	Map
IL	Northwestern University	Chicago60611	NCT06649812	Map
IL	NW Uni C and T Sciences Ins	Chicago60611	NCT06868212	Map
IL	Rush University Medical Center	Chicago60607	NCT06846281	Map
IL	University of Chicago Medical Center	Chicago60637	NCT03331198	Map
IL	University Of Chicago Medical Center	Chicago60637	NCT03331198	Map
IL	University of Chicago Medical Centr	Chicago60637	NCT06744920	Map
IL	Carle at The Riverfront	Danville61832	NCT04840602	Map
IL	Cancer Care Specialists of Illinois - Decatur	Decatur62526	NCT04840602	Map
IL	Northwestern Medicine Cancer Center Kishwaukee	DeKalb60115	NCT06649812	Map
IL	Carle Physician Group-Effingham	Effingham62401	NCT04840602	Map
IL	Crossroads Cancer Center	Effingham62401	NCT04840602	Map
IL	Northwestern Medicine Cancer Center Delnor	Geneva60134	NCT06649812	Map
IL	Endeavor Health	Glenview60077	NCT06865651	Map
IL	Northwestern Medicine Glenview Outpatient Center	Glenview60026	NCT06649812	Map
IL	Northwestern Medicine Grayslake Outpatient Center	Grayslake60030	NCT06649812	Map
IL	Hope and Healing Cancer Services	Hinsdale60521	NCT05963074	Map
IL	Northwestern Medicine Lake Forest Hospital	Lake Forest60045	NCT06649812	Map
IL	Carle Physician Group-Mattoon/Charleston	Mattoon61938	NCT04840602	Map
IL	Midwest Allergy Sinus Asthma SC	Normal61761	NCT06868212	Map
IL	Cancer Care Center of O'Fallon	O'Fallon62269	NCT04840602	Map
IL	Clinical Res Ctr of S Illinois	O'Fallon62269	NCT06868212	Map
IL	Northwestern Medicine Oak Brook	Oak Brook60523	NCT06649812	Map
IL	Northwestern Medicine Orland Park	Orland Park60462	NCT06649812	Map
IL	Asthma and Allergy Center of Chicago S C	River Forest60305	NCT06868212	Map
IL	Memorial Hospital East	Shiloh62269	NCT06649812	Map
IL	Endeavor Health Clinical Trials Center	Skokie60077	NCT06868212	Map
IL	Southern Illinois University School of Medicine	Springfield62702	NCT04840602	Map
IL	Springfield Clinic	Springfield62702	NCT04840602	Map
IL	Springfield Clinic	Springfield62702	NCT05963074	Map
IL	Springfield Memorial Hospital	Springfield62781	NCT04840602	Map
IL	Carle Cancer Center	Urbana61801	NCT04840602	Map
IL	Northwestern Medicine Cancer Center Warrenville	Warrenville60555	NCT06649812	Map
IL	Accellacare Duly Health and Care	Wheaton60189	NCT06868212	Map
IN	Deaconess Clin Allerg Res Inst	Evansville47715	NCT06868212	Map
IN	Parkview Research Center at Parkview Regional Medical Center ( Site 0002)	Fort Wayne46845	NCT06136559	Map
IN	Franciscan St. Francis Health - Indiana Blood and Marrow Transplantation (IBMT)	Indianapolis46237	NCT03331198	Map
IN	Southern IN Clinical Trials	New Albany47150	NCT06868212	Map
IA	Mary Greeley Medical Center	Ames50010	NCT04840602	Map
IA	Mary Greeley Medical Center	Ames50010	NCT06649812	Map
IA	McFarland Clinic - Ames	Ames50010	NCT04840602	Map
IA	McFarland Clinic - Ames	Ames50010	NCT06649812	Map
IA	McFarland Clinic PC	Ames50010	NCT06868212	Map
IA	Mercy Hospital	Cedar Rapids52403	NCT06649812	Map
IA	Oncology Associates at Mercy Medical Center	Cedar Rapids52403	NCT06649812	Map
IA	McFarland Clinic - Trinity Cancer Center	Fort Dodge50501	NCT04840602	Map
IA	McFarland Clinic - Trinity Cancer Center	Fort Dodge50501	NCT06649812	Map
IA	Iowa City VA Health Care System	Iowa City52246	NCT05963074	Map
IA	McFarland Clinic - Marshalltown	Marshalltown50158	NCT04840602	Map
IA	McFarland Clinic - Marshalltown	Marshalltown50158	NCT06649812	Map
IA	University of Iowa Health Care. ( Site 0017)	Waukee50263	NCT06136559	Map
IA	University of Iowa Health Care. ( Site 0057)	Waukee50263	NCT06136559	Map
KS	University of Kansas Hospital	Kansas City66160	NCT06846281	Map
KS	University of Kansas Hospital	Kansas City66160	NCT07225504	Map
KY	Equity Medical LLC	Bowling Green42104	NCT06868212	Map
KY	Saint Elizabeth Healthcare ( Site 0041)	Edgewood41017	NCT06136559	Map
KY	Family Allergy And Asthma Rsch Inst	Louisville40215	NCT06868212	Map
KY	Norton Healthcare - Norton Cancer Institute	Louisville40202	NCT03331198	Map
KY	Allergy and Asthma Specialist P S C	Owensboro42301	NCT06868212	Map
LA	Ochsner Health Center	Baton Rouge70816	NCT06868212	Map
LA	Velocity Clinical Research	Lafayette70508	NCT06868212	Map
LA	Ochsner Medical Center Jefferson	New Orleans70121	NCT06649812	Map
MD	Chesapeake Clinical Research Inc	Baltimore21236	NCT06868212	Map
MD	Johns Hopkins U School of Med	Baltimore21205	NCT06868212	Map
MD	University of Maryland, Baltimore /ID# 242218	Baltimore21201	NCT05283720	Map
MD	American Oncology Partners of Maryland, PA	Bethesda20817	NCT05254743	Map
MD	Mid Atlantic Epilepsy and Sleep Ctr	Bethesda20817-1807	NCT06744920	Map
MD	Mid Atlantic Epilepsy and Sleep Ctr	Bethesda20817-1807	NCT07225504	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT03223610	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT06649812	Map
MD	Institute for Asthma and Allergy PC	Chevy Chase20815	NCT06868212	Map
MD	AllerVie Clin Res Glenn Dale	Glenn Dale20769	NCT06868212	Map
MD	MedStar Montgomery Medical Center	Olney20832	NCT06846281	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT03331198	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT04421560	Map
MA	Boston Specialists LLC	Boston02111	NCT06868212	Map
MA	Brigham & Women's Hospital	Boston02215	NCT07052695	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT03328078	Map
MA	Dana Farber Cancer Institute	Boston02115	NCT04421560	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT07052695	Map
MA	Massachusetts General Hospital	Boston02114	NCT03331198	Map
MA	Neuromuscular Diagnostic Center	Boston02114	NCT06744920	Map
MA	Tufts Medical Center	Boston02111	NCT06846281	Map
MA	Lahey Hospital and Medical Center	Burlington01805	NCT06846281	Map
MA	Neuro Institute of New England P C	Foxborough02035	NCT07225504	Map
MA	Neurology Center of New England PC	Foxborough02035	NCT06846281	Map
MI	ClinSite Inc	Ann Arbor48106-0525	NCT06868212	Map
MI	Trinity Health Saint Joseph Mercy Hospital Ann Arbor	Ann Arbor48106	NCT04840602	Map
MI	University of Michigan Comprehensive Cancer Center	Ann Arbor48109-5362	NCT03331198	Map
MI	University Of Michigan Comprehensive Cancer Center	Ann Arbor48109	NCT03331198	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Brighton	Brighton48114	NCT04840602	Map
MI	Trinity Health Medical Center - Brighton	Brighton48114	NCT04840602	Map
MI	Derm Institute West Michigan PLLC	Caledonia49316	NCT06868212	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Canton	Canton48188	NCT04840602	Map
MI	Trinity Health Medical Center - Canton	Canton48188	NCT04840602	Map
MI	Chelsea Hospital	Chelsea48118	NCT04840602	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Chelsea48118	NCT04840602	Map
MI	Hematology Oncology Consultants-Clarkston	Clarkston48346	NCT04840602	Map
MI	Henry Ford Macomb Hospital-Clinton Township	Clinton Township48038	NCT04840602	Map
MI	Barbara Ann Karmanos Cancer Institute	Detroit48201	NCT03331198	Map
MI	Henry Ford Hospital	Detroit48202	NCT04840602	Map
MI	Henry Ford Hospital	Detroit48202	NCT06868212	Map
MI	Michigan State University-Department of Neurology	East Lansing48824	NCT06744920	Map
MI	Michigan Institute of Neurological	Farmington Hills48334	NCT06846281	Map
MI	Michigan Institute of Neurological	Farmington Hills48334	NCT07225504	Map
MI	Cancer Hematology Centers - Flint	Flint48503	NCT04840602	Map
MI	Genesys Hurley Cancer Institute	Flint48503	NCT04840602	Map
MI	Hurley Medical Center	Flint48503	NCT04840602	Map
MI	Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011)	Grand Rapids49503	NCT06136559	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT04840602	Map
MI	Trinity Health Saint Mary Mercy Livonia Hospital	Livonia48154	NCT04840602	Map
MI	Henry Ford Medical Center-Columbus	Novi48377	NCT04840602	Map
MI	Memorial HC Ins for Neuroscience	Owosso48867	NCT06846281	Map
MI	Michigan Healthcare Professionals Pontiac	Pontiac48341	NCT04840602	Map
MI	Newland Medical Associates-Pontiac	Pontiac48341	NCT04840602	Map
MI	Trinity Health Saint Joseph Mercy Oakland Hospital	Pontiac48341	NCT04840602	Map
MI	MyMichigan Medical Center Saginaw	Saginaw48601	NCT04840602	Map
MI	MyMichigan Medical Center Tawas	Tawas City48764	NCT04840602	Map
MI	Revival Research Institute	Troy48084	NCT06868212	Map
MI	Somerset Skin Centre	Troy48084	NCT06868212	Map
MI	Henry Ford West Bloomfield Hospital	West Bloomfield48322	NCT04840602	Map
MI	Huron Gastroenterology PC	Ypsilanti48106	NCT04840602	Map
MI	Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Ypsilanti48197	NCT04840602	Map
MN	Essentia Health Saint Joseph's Medical Center	Brainerd56401	NCT06649812	Map
MN	Essentia Health - Deer River Clinic	Deer River56636	NCT06649812	Map
MN	Essentia Health Cancer Center	Duluth55805	NCT06649812	Map
MN	Essentia Health Hibbing Clinic	Hibbing55746	NCT06649812	Map
MN	Abbott-Northwestern Hospital	Minneapolis55407	NCT04840602	Map
MN	Clinical Research Institute	Minneapolis55402	NCT06868212	Map
MN	Hennepin County Medical Center	Minneapolis55415	NCT04840602	Map
MN	Minnesota Oncology Hematology P A	Minneapolis55404	NCT05963074	Map
MN	University of Minnesota	Minneapolis55455	NCT06868212	Map
MN	University of Minnesota/Masonic Cancer Center	Minneapolis55455	NCT06536049	Map
MN	Mayo Clinic	Rochester55905	NCT03328078	Map
MN	Mayo Clinic	Rochester55905	NCT03331198	Map
MN	Mayo Clinic	Rochester55905	NCT03331198	Map
MN	Mayo Clinic - Rochester	Rochester55905	NCT06868212	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT04840602	Map
MN	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park55416	NCT04840602	Map
MN	Regions Hospital ( Site 0042)	Saint Louis Park55416	NCT06136559	Map
MN	Regions Hospital	Saint Paul55101	NCT04840602	Map
MN	United Hospital	Saint Paul55102	NCT04840602	Map
MN	Essentia Health Sandstone	Sandstone55072	NCT06649812	Map
MN	Essentia Health Virginia Clinic	Virginia55792	NCT06649812	Map
MO	Saint Francis Medical Center	Cape Girardeau63703	NCT04840602	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT06649812	Map
MO	ENT and Allergy Center of Missouri	Columbia65201	NCT06868212	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT06649812	Map
MO	Kansas City VA Medical Center, Kansas City, MO	Kansas City64128-2226	NCT06520098	Map
MO	MidAmerica Cancer Care, LLC ( Site 0043)	Kansas City64132	NCT06136559	Map
MO	Research Medical Center	Kansas City64132	NCT05963074	Map
MO	Heartland Regional Medical Center	Saint Joseph64506	NCT04840602	Map
MO	Mercy Hospital South	St Louis63128	NCT04840602	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT06649812	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT06649812	Map
MO	The Clinical Research Center	St Louis63141	NCT06868212	Map
MO	WA Uni School Of Med	St Louis63110	NCT06846281	Map
MO	Washington University	St Louis63141	NCT06868212	Map
MO	Washington University School of Medicine	St Louis63110	NCT06649812	Map
MT	Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0052)	Billings59102	NCT06136559	Map
MT	Saint Vincent Frontier Cancer Center	Billings59102	NCT04840602	Map
MT	St. Vincent Frontier Cancer Center	Billings59102	NCT05254743	Map
NE	Nebraska Medicine-Bellevue	Bellevue68123	NCT06649812	Map
NE	Somnos Clinical Research	Lincoln68510	NCT06868212	Map
NE	Fred and Pamela Buffett Cancer Center	Omaha68198	NCT03328078	Map
NE	Nebraska Medicine-Village Pointe	Omaha68118	NCT06649812	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT03331198	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT06649812	Map
NE	University Of Nebraska Medical Center	Omaha68198	NCT03331198	Map
NV	Allergy and Asthma Center of Las Vegas	Las Vegas89128	NCT06868212	Map
NV	Cleveland Clinic Foundation	Las Vegas89106	NCT06846281	Map
NV	Las Vegas Dermatology	Las Vegas89144	NCT06868212	Map
NJ	Memorial Sloan Kettering Basking Ridge	Basking Ridge07920	NCT04840602	Map
NJ	Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge07920	NCT07082868	Map
NJ	Memorial Sloan-Kettering Cancer Center (MSKCC) - Basking Ridge	Basking Ridge07920	NCT03331198	Map
NJ	Hudson Essex Allergy-Circuit Clinical	Belleville07109	NCT06868212	Map
NJ	Astera Cancer Care	Edison08820	NCT03331198	Map
NJ	Hunterdon Hematology Oncology	Flemington08822	NCT05963074	Map
NJ	Hackensack University Medical Center	Hackensack07601	NCT03331198	Map
NJ	John Theurer Cancer Center	Hackensack07601-2191	NCT03331198	Map
NJ	John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016)	Hackensack07601	NCT06136559	Map
NJ	Circuit Clinical Mercer Algy Pulm	Hamilton08619	NCT06868212	Map
NJ	Allergy Asthma Assoc Monmouth	Little Silver07739	NCT06868212	Map
NJ	Memorial Sloan Kettering Monmouth	Middletown07748	NCT04840602	Map
NJ	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown07748	NCT07082868	Map
NJ	Memorial Sloan Kettering Bergen	Montvale07645	NCT04840602	Map
NJ	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale07645	NCT07082868	Map
NJ	Atlantic Health System / Morristown Medical Center	Morristown07960	NCT03331198	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT03331198	Map
NJ	Allergy Partners of New Jersey PC	Ocean Township07712	NCT06868212	—
NJ	Circuit Clinical	Riverdale07457	NCT06868212	Map
NJ	Holy Name Medical Center	Teaneck07666	NCT06846281	Map
NM	University of New Mexico	Albuquerque87131-0001	NCT06846281	Map
NM	University of New Mexico Hospital	Albuquerque87106	NCT07225504	Map
NY	New York Oncology Hematology, P.C. ( Site 0069)	Albany12208	NCT06136559	Map
NY	Dent Neurological Institute	Buffalo14209	NCT06744920	Map
NY	Roswell Park Cancer Institute ( Site 0023)	Buffalo14263	NCT06136559	Map
NY	Roswell Park Comprehensive Cancer Center	Buffalo14263	NCT03328078	Map
NY	SUNY Buffalo The Jacobs Neuro Inst	Buffalo14203	NCT06846281	Map
NY	Memorial Sloan Kettering Commack	Commack11725	NCT04840602	Map
NY	Memorial Sloan Kettering Commack (Limited Protocol Activities)	Commack11725	NCT07082868	Map
NY	Memorial Sloan Kettering Westchester	Harrison10604	NCT04840602	Map
NY	Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison10604	NCT07082868	Map
NY	Northwell Health - Monter Cancer Center /ID# 245435	Lake Success11042	NCT05283720	Map
NY	Icahn School of Medicine at Mount Sinai /ID# 242123	New York10029	NCT05283720	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT03328078	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT04421560	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT04840602	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York10065	NCT07082868	Map
NY	Mt Sinai	New York10029	NCT03328078	Map
NY	Weill Cornell Medical College	New York10065	NCT03331198	Map
NY	Hematology Oncology Associates of Rockland	Nyack10960	NCT05963074	Map
NY	University of Rochester	Rochester14642	NCT04840602	Map
NY	Stony Brook University	Stony Brook11794-8160	NCT03331198	Map
NY	Equity Medical	The Bronx10455	NCT06868212	Map
NY	Montefiore Medical Center	The Bronx10467	NCT06868212	Map
NY	Memorial Sloan Kettering Nassau	Uniondale11553	NCT04840602	Map
NY	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale11553	NCT07082868	Map
NY	RPCI Oncology, PC- Northtowns ( Site 0061)	Williamsville14221	NCT06136559	Map
NC	Allergy Partners Of West NC	Asheville28801	NCT06868212	Map
NC	UNC DermatologyandSkinCancer Ctr	Chapel Hill27516	NCT06868212	Map
NC	Carolina Oncology Specialists, PA ( Site 0054)	Charlotte28207	NCT06136559	Map
NC	Carolinas Medical Center/Levine Cancer Institute	Charlotte28203	NCT04840602	Map
NC	Southeastern Medical Oncology Center-Clinton	Clinton28328	NCT04840602	Map
NC	Duke University Medical Center	Durham27705	NCT03331198	Map
NC	Duke University Medical Center	Durham27710	NCT03331198	Map
NC	Duke University Medical Center	Durham27710	NCT06649812	Map
NC	Duke University Medical Center, Duke Cancer Center	Durham27710	NCT03328078	Map
NC	Durham VA Medical Center, Durham, NC	Durham27705-3875	NCT06520098	Map
NC	Levine Cancer Institute-Gaston	Gastonia28054	NCT04840602	Map
NC	Southeastern Medical Oncology Center ( Site 0049)	Goldsboro27534	NCT06136559	Map
NC	Southeastern Medical Oncology Center-Goldsboro	Goldsboro27534	NCT04840602	Map
NC	East Carolina University - Brody School of Medicine /ID# 242506	Greenville27834	NCT05283720	Map
NC	Southeastern Medical Oncology Center-Jacksonville	Jacksonville28546	NCT04840602	Map
NC	Atrium Health Union/LCI-Union	Monroe28112	NCT04840602	Map
NC	Velocity Clinical Research	Raleigh27607	NCT06846281	Map
ND	Essentia Health Cancer Center-South University Clinic	Fargo58103	NCT06649812	Map
ND	Sanford Health	Fargo58122	NCT06846281	Map
OH	Premier Health	Centerville45459	NCT06846281	Map
OH	Bernstein Clinical Research Center	Cincinnati45231	NCT06868212	Map
OH	Oncology Hematology Care	Cincinnati45242	NCT05963074	Map
OH	Univ of Cincinnati Medical Center	Cincinnati45219	NCT06744920	Map
OH	Univ of Cincinnati Medical Center	Cincinnati45219	NCT06846281	Map
OH	Cleveland Clinic	Cleveland44195	NCT03328078	Map
OH	Cleveland Clinic Foundation	Cleveland44195	NCT06744920	Map
OH	Cleveland Clinic Foundation	Cleveland44195	NCT06846281	Map
OH	University Hospitals Cleveland Medical Center	Cleveland44106	NCT03331198	Map
OH	University Hospitals Seidman Cancer Center (Case Western)	Cleveland44106-5061	NCT03331198	Map
OH	CR Services Acquisition US	Columbus43213	NCT06868212	Map
OH	Ohio Health Research Institute	Columbus43214	NCT06846281	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06536049	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06649812	Map
OH	The Ohio State University Comprehensive Cancer Center	Columbus43210	NCT03331198	Map
OH	The Ohio State University- James Cancer Hospital	Columbus43210	NCT01804686	Map
OH	Wright State University	Fairborn45324	NCT06868212	Map
OH	Licking Memorial Hospital	Newark43055	NCT04840602	Map
OH	Toledo Institute of Clinical Research	Toledo43617	NCT06868212	Map
OK	Unity Clinical Research	Oklahoma City73118	NCT06868212	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06649812	Map
OK	University of Oklahoma Health Sciences Center (Stephenson Cancer Center)	Oklahoma City73104	NCT03331198	Map
OK	University of Oklahoma Peggy and Charles Stephenson Cancer Center	Oklahoma City73104	NCT03331198	Map
OK	Vital Prospects Clinical Research Institute	Tulsa74136	NCT06868212	Map
OR	Willamette Valley Cancer Center	Eugene97401	NCT01804686	Map
OR	Willamette Valley Cancer Institute and Research Center	Eugene97401	NCT05963074	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT04840602	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT06649812	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT04840602	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT06649812	Map
OR	OHSU Knight Cancer Institute	Portland97239	NCT05963074	Map
OR	OHSU Knight Cancer Institute	Portland97239	NCT06357676	Map
OR	Oregon Health Sciences University	Portland97239	NCT06868212	Map
OR	Oregon Medical Research Center	Portland97223	NCT06868212	Map
OR	Providence Neurological Specialties West	Portland97225	NCT03328078	Map
OR	Providence Portland Medical Center	Portland97213	NCT04840602	Map
OR	Providence Portland Medical Center	Portland97213	NCT06649812	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT04840602	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT06649812	Map
PA	Consultants in Medical Oncology and Hematology (CMOH) ( Site 8002)	Broomall19008	NCT06136559	Map
PA	Thomas Jefferson University	Philadelphia19107	NCT03331198	Map
PA	Thomas Jefferson University - Clinical Research Institute	Philadelphia19107	NCT03331198	Map
PA	Thomas Jefferson University Hospital	Philadelphia19107	NCT06649812	Map
PA	University of Pennsylvania - Perelman Center for Advanced Medicine	Philadelphia19104	NCT03331198	Map
PA	University of Pennsylvania Perelman Center for Advanced Medicine	Philadelphia19104	NCT03331198	Map
PA	Allergy and Clinical Immunology Associates	Pittsburgh15241	NCT06868212	Map
PA	University of Pittsburgh Medical Center	Pittsburgh15213	NCT06744920	Map
PA	UPMC Hillman Cancer Center	Pittsburgh15232	NCT03331198	Map
PA	UPMC Hilman Cancer Center	Pittsburgh15232	NCT03328078	Map
PA	Cancer Care Associates Of York ( Site 0005)	York17403	NCT06136559	Map
SC	Medical Univ Of SC Medical Ctr	Charleston29425	NCT06868212	Map
SC	Allergic Disease and Asthma Center	Greenville29607	NCT06868212	Map
SC	Premier Neurology	Greenville29605	NCT06846281	Map
SC	Premier Neurology	Greenville29605	NCT07225504	Map
SC	Tribe Clinical Research LLC	Greenville29601	NCT06868212	Map
SC	Charleston ENT and Allergy	North Charleston29406	NCT06868212	Map
SC	National Allergy and Asthma Research LLS	North Charleston29420	NCT06868212	Map
SD	Avera Medical Group	Sioux Falls57105	NCT01804686	Map
TN	Tennessee Oncology-Chattanooga ( Site 0045)	Chattanooga37404	NCT06136559	Map
TN	Neurology Clinic PC	Cordova38018	NCT07225504	Map
TN	Sibyl Wray MD Neurology PC	Knoxville37922	NCT06846281	Map
TN	International Clinical Research Tennessee LCC	Murfreesboro37130	NCT06868212	Map
TN	Sarah Cannon Research Institute - Tennessee Oncology	Nashville37203	NCT03331198	Map
TN	Sarah Cannon Research Institute SCRI	Nashville37203	NCT05254743	Map
TN	Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031)	Nashville37203	NCT06136559	Map
TX	Arlington Center for Dermatology	Arlington76011	NCT06868212	Map
TX	Austin Regional Clinic	Austin78731	NCT06846281	Map
TX	Orion Clinical Research	Austin78759	NCT06868212	Map
TX	Texas Oncology - Central/South Texas ( Site 8008)	Austin78705	NCT06136559	Map
TX	Bellaire Dermatology Associates	Bellaire77401	NCT06868212	Map
TX	Baylor University Medical Center	Dallas75246	NCT03331198	Map
TX	Pharma Research and Amp Consult	Dallas75231	NCT06868212	Map
TX	Reveal Research Institute	Dallas75230	NCT06868212	Map
TX	Univ of Texas Southwest Med Center	Dallas75390-9034	NCT06846281	Map
TX	University of Texas Southwestern Medical Center	Dallas75390	NCT03331198	Map
TX	Western Sky Medical Research	El Paso79924	NCT06868212	Map
TX	John Peter Smith Hospital	Fort Worth76104	NCT06846281	Map
TX	Texas Oncology-Fort Worth Cancer Center	Fort Worth76104	NCT05963074	Map
TX	The Center for Cancer and Blood Disorders ( Site 0032)	Fort Worth76104	NCT06136559	Map
TX	Center for Clinical Studies	Houston77030	NCT06868212	Map
TX	Houston Methodist Hospital	Houston77030	NCT06744920	Map
TX	M D Anderson Cancer Center	Houston77030	NCT03128879	Map
TX	The University of Texas - MD Anderson Cancer Center	Houston77030	NCT03331198	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT03328078	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT03331198	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT05963074	Map
TX	UT Health Science Center	Houston77030	NCT06744920	Map
TX	Sante Clinical Research	Kerrville78028	NCT06868212	Map
TX	Lumi Research	Kingwood77339	NCT05254743	Map
TX	Saturn Research Solution	Plano75024	NCT07225504	Map
TX	Saturn Research Solutions LLC	Plano75024	NCT06846281	Map
TX	Andante Research	San Antonio78229	NCT06868212	Map
TX	RFSA Dermatology	San Antonio78213	NCT06868212	Map
TX	Texas Oncology - San Antonio ( Site 8006)	San Antonio78217	NCT06136559	Map
TX	Texas Oncology-Gulf Coast	The Woodlands77380	NCT05963074	Map
TX	Texas Oncology - Northeast Texas ( Site 8012)	Tyler75702	NCT06136559	Map
UT	University Of Utah	Murray84107	NCT06868212	Map
UT	Community Cancer Trials of Utah	Ogden84405	NCT05963074	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT03331198	Map
UT	Huntsman Cancer Institute, University of Utah	Salt Lake City84112	NCT03328078	Map
UT	University of Utah (Data Collection Only)	Salt Lake City84112	NCT07082868	Map
UT	Allergy Associates of Utah	Sandy City84093	NCT06868212	Map
VT	University of Vermont and State Agricultural College	Burlington05405	NCT06649812	Map
VT	University of Vermont Medical Center	Burlington05401	NCT06649812	Map
VA	University of Virginia Cancer Center	Charlottesville22908	NCT06649812	Map
VA	University of Virginia Cancer Center ( Site 0040)	Charlottesville22903	NCT06136559	Map
VA	Inova Schar Cancer Institute ( Site 0015)	Fairfax22031	NCT06136559	Map
VA	Virginia Cancer Specialists	Manassas20110	NCT05963074	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT04840602	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT06649812	Map
VA	Virginia Cancer Institute	Richmond23230	NCT05254743	Map
VA	Virginia Commonwealth University (VCU) Medical Center ( Site 0030)	Richmond23298	NCT06136559	Map
VA	Forefront Dermatology	Vienna22182	NCT06868212	Map
VA	Virginia Oncology Associates	Virginia Beach23456	NCT05963074	Map
WA	Bellingham Asthma Allergy and Immunology	Bellingham98225	NCT06868212	Map
WA	Swedish Cancer Institute-Edmonds	Edmonds98026	NCT04840602	Map
WA	Swedish Cancer Institute-Issaquah	Issaquah98029	NCT04840602	Map
WA	Fred Hutchinson Cancer Research Center	Seattle98109	NCT03331198	Map
WA	Seattle Cancer Center Alliance	Seattle98109	NCT03331198	Map
WA	Swedish Medical Center - Seattle /ID# 242269	Seattle98104	NCT05283720	Map
WA	Swedish Medical Center-First Hill	Seattle98122	NCT04840602	Map
WA	Swedish Medical Center-First Hill	Seattle98122	NCT06649812	Map
WA	University of WA Division of Cardio	Seattle98195	NCT06744920	Map
WA	University of Washington Medical Center	Seattle98195	NCT03328078	Map
WA	University of Washington MS Clinic	Seattle98133	NCT07225504	Map
WA	VA Puget Sound Health Care System Seattle Division, Seattle, WA	Seattle98108-1532	NCT06520098	Map
WA	VA Puget Sound Healthcare System	Seattle98108	NCT05963074	Map
WA	Citta Clinical Research	Spokane99202	NCT07225504	Map
WA	Medical Oncology Associates, PS	Spokane99208	NCT05254743	Map
WA	Medical Oncology Associates, PS (dba Summit Cancer Centers) ( Site 0010)	Spokane99208	NCT06136559	Map
WA	Northwest Cancer Specialists PC	Vancouver98684	NCT05963074	Map
WI	ThedaCare Regional Cancer Center	Appleton54911	NCT04840602	Map
WI	Duluth Clinic Ashland	Ashland54806	NCT06649812	Map
WI	Center for Neurological Disorders G	Greenfield53228-1321	NCT06744920	Map
WI	Center for Neurological Disorders G	Greenfield53228-1321	NCT06846281	Map
WI	Mercyhealth Hospital and Cancer Center - Janesville	Janesville53548	NCT06649812	Map
WI	Gundersen Lutheran Medical Center	La Crosse54601	NCT04840602	Map
WI	Gundersen Lutheran Medical Center	La Crosse54601	NCT06649812	Map
WI	SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical ( Site 0048)	Madison53715	NCT06136559	Map
WI	University Hospital and UW Health Clinics ( Site 0006)	Madison53792	NCT06136559	Map
WI	Froedtert Hospital BMT Medical College of Wisconsin	Milwaukee53226	NCT03331198	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT03331198	Map
WI	Essentia Health-Spooner Clinic	Spooner54801	NCT06649812	Map
WI	Essentia Health Saint Mary's Hospital - Superior	Superior54880	NCT06649812	Map

Ibrutinib clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	withdrawn	not yet recruiting	unknown	approved for marketing	available	Total
Early P1			2	1						3
P1	2	15	36	14	7	1				75
P1/P2	9	5	28	5	2		2			51
P2	14	35	55	21	8	1	14			148
P2/P3	1		1				1			3
P3	9	16	22	1	2		3			53
P4		1	2			1				4
N/A	1	2	6				3	2	1	15

Recruiting Ibrutinib clinical trials (39)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07474961	BLOOD-doseBLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.	P4	Waldenstrom Macroglobulinaemia	400	Mar 2027
NCT07225504	REMASTERA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis	P3	Secondary Progressive Multiple Sclerosis (SPMS)	1,275	Nov 2025
NCT06744920	RELIEVEA Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis	P3	Generalized Myasthenia Gravis	180	Feb 2025
NCT07456891	Remibrutinib Open Label Roll-over Post-trial Access Protocol	P3	Indication of the Parent Protocol	212	Apr 2026
NCT07377578	A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma	P3	Mantle Cell Lymphoma	394	Feb 2026
NCT07052695	Mosunetuzumab for CLL MRD Clearance	P1/P2	Leukemia	40	Nov 2025
NCT05283720	SCA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma	P2	Non-Hodgkin Lymphoma	496	Jun 2022
NCT06136559	MK-1026A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)	P3	Chronic Lymphocytic Leukemia	1,200	Dec 2023
NCT06482684	CARMANCAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma	P2	Mantle Cell Lymphoma	150	Feb 2024
NCT06846281	Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.	P3	Relapsing Multiple Sclerosis	360	Jul 2025
NCT06520098	Benefit VAA Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	P2	Chronic Lymphocytic Leukemia	100	Oct 2025
NCT07222956	RemiSevenA Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS	P2	Multiple Sclerosis (MS) - Relapsing-remitting	20	Jun 2026
NCT04061512	RAINBOWRituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia	P2/P3	Waldenstrom Macroglobulinemia	148	Feb 2020
NCT01804686	CAN3001A Long-term Extension Study of PCI-32765 (Ibrutinib)	P3	Chronic Lymphocytic Leukemia	700	Sep 2013
NCT06357676	Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial	P1/P2	Mantle Cell Lymphoma	27	May 2025
NCT05963074	TAILORA Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia	P2	Leukemia, Lymphocytic, Chronic, B-Cell	320	May 2024
NCT05998642	Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma	P2	Non-hodgkin Lymphoma	30	Feb 2024
NCT05106296	Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer	P1	Ependymoma	37	Feb 2022
NCT07169565	Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia	P1	Waldenström Macroglobulinemia (WM)	21	Sep 2025
NCT07082868	CNSLA Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)	P1	Primary Central Nervous System Lymphoma (PCNSL)	26	Aug 2025
NCT04840602	Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma	P2	Lymphoplasmacytic Lymphoma	92	Jan 2022
NCT06958705	Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy	P2	Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)	79	Dec 2025
NCT05254743	BRUIN-CLL-314A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	P3	Chronic Lymphocytic Leukemia	737	Jul 2022
NCT04758975	VALUABLEVenetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)	P2	Chronic Lymphocytic Leukemia (CLL)	55	Sep 2022
NCT03980002	BDHCLL001A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL	P2	Chronic Lymphocytic Leukemia	50	May 2019
NCT04771507	IbruOnOffA Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)	P1/P2	Chronic Lymphocytic Leukemia	50	Feb 2018
NCT03223610	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma	P1/P2	Lymphoma	155	Feb 2018
NCT03331198	CLLStudy Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)	P1/P2	Leukemia, Lymphocytic, Chronic, B-Cell	320	Nov 2017
NCT06536049	Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma	P1/P2	Recurrent Diffuse Large B-Cell Lymphoma	38	Apr 2025
NCT06299540	QOLIBRIBenefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia	—	Leukemia, Lymphocytic, Chronic, B-Cell	180	May 2024
NCT06865651	LOU064Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria	P2	Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)	44	May 2025
NCT04908228	FIGHTFixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL	P2	Chronic Lymphocytic Leukemia	53	Dec 2021
NCT06649812	Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma	P2	High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements	120	Oct 2025
NCT03128879	Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL	P2	Chronic Lymphocytic Leukemia	90	Jun 2017
NCT06868212	RECLAIMA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines	P3	Chronic Spontaneous Urticaria (CSU)	400	Jul 2025
NCT04421560	Pembrolizumab, Ibrutinib and Rituximab in PCNSL	P1/P2	Primary Central Nervous System Lymphoma	37	Aug 2020
NCT05694312	Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL	P2	Autoimmune Hemolytic Anemia	45	Nov 2023
NCT03328078	CA-4948CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)	P1/P2	Relapsed Hematologic Malignancy	152	Dec 2017
NCT04494503	Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL	P1/P2	Chronic Lymphocytic Leukemia	123	Aug 2020

Ibrutinib clinical trials by indication

Chronic Lymphocytic Leukemia (53)

NCT	Acronym	Phase	Status	Title
NCT02514083	—	P2	active not recruiting	A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
NCT06136559	MK-1026	P3	recruiting	A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06520098	Benefit VA	P2	recruiting	A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT01804686	CAN3001	P3	recruiting	A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT03422393	—	P1	active not recruiting	Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
NCT03960840	—	P1/P2	active not recruiting	Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03701282	—	P3	active not recruiting	Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
NCT02629809	—	P2	active not recruiting	Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
+ 45 more, see All trials below.

Mantle Cell Lymphoma (19)

NCT	Acronym	Phase	Status	Title
NCT07377578	—	P3	recruiting	A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT06482684	CARMAN	P2	recruiting	CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
NCT04802590	—	P2	active not recruiting	Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
NCT03617484	—	P2	withdrawn	Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
NCT02682641	—	P2	active not recruiting	Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
NCT06357676	—	P1/P2	recruiting	Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
NCT03282396	—	P2	active not recruiting	Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
NCT03710772	—	P2	active not recruiting	Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
+ 11 more, see All trials below.

Leukemia, Lymphocytic, Chronic, B-Cell (16)

NCT	Acronym	Phase	Status	Title
NCT03462719	GLOW	P3	active not recruiting	A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05963074	TAILOR	P2	recruiting	A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT03331198	CLL	P1/P2	recruiting	Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT06299540	QOLIBRI	N/A	recruiting	Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
NCT04876092	—	P1	completed	A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL
NCT02666898	ICLL07GAI	P2	completed	Phase II Trial GA101 Inbrutinib B CLL
NCT03190330	—	P4	completed	A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
NCT03425591	FIRE	N/A	completed	A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
+ 8 more, see All trials below.

Lymphoma (11)

NCT	Acronym	Phase	Status	Title
NCT04739813	—	P1	active not recruiting	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
NCT03223610	—	P1/P2	recruiting	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
NCT02436707	—	P2	active not recruiting	Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCT01974440	SELENE	P3	completed	A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
NCT02756247	—	P1	completed	A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
NCT02733042	FUSION NHL 001	P1/P2	completed	A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
NCT02760485	INCB039110	P1/P2	completed	A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT01855750	—	P3	completed	A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
+ 3 more, see All trials below.

Waldenstrom Macroglobulinemia (7)

NCT	Acronym	Phase	Status	Title
NCT04061512	RAINBOW	P2/P3	recruiting	Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
NCT04263480	CZAR-1	P2	active not recruiting	Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
NCT04273139	—	P2	active not recruiting	Ibrutinib + Venetoclax in Untreated WM
NCT03620903	—	P2	active not recruiting	Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
NCT04042376	PCI-32765	P4	completed	A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)
NCT04062448	WM	P2	completed	A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)
NCT03679624	—	P2	terminated	Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Healthy (6)

NCT	Acronym	Phase	Status	Title
NCT02877225	—	P1	completed	Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule
NCT02841150	—	P1	completed	Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules
NCT02638116	—	P1	completed	A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
NCT02390609	—	P1	completed	A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults
NCT02271438	—	P1	completed	A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants
NCT01626651	—	P1	completed	A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants

Diffuse Large B Cell Lymphoma (5)

NCT	Acronym	Phase	Status	Title
NCT03129828	ImbruVeRCHOP	P1/P2	completed	Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2
NCT03399513	R-CHOEP-brut	P2	completed	Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma
NCT02955628	—	P2	unknown	RICE-ibrutinib in Relapsed DLBCL
NCT04025593	—	P2	unknown	Biomarker Guided Treatment in DLBCL
NCT03949062	—	P2	unknown	Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

Recurrent Diffuse Large B-Cell Lymphoma (4)

NCT	Acronym	Phase	Status	Title
NCT06536049	—	P1/P2	recruiting	Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
NCT01955499	—	P1	active not recruiting	Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT03440567	—	P1	completed	Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
NCT02874404	—	P2	completed	TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lymphoma, Mantle-Cell (4)

NCT	Acronym	Phase	Status	Title
NCT04662255	BRUIN-MCL-321	P3	active not recruiting	Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT05431179	—	P3	withdrawn	A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT05564052	VEGA	P2	completed	A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
NCT02419560	—	P1	completed	Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

Chronic Lymphocytic Leukemia (CLL) (4)

NCT	Acronym	Phase	Status	Title
NCT04685915	—	P2	withdrawn	Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
NCT04758975	VALUABLE	P2	recruiting	Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
NCT05105841	IV	P2	completed	Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT03400176	—	P1	terminated	VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Recurrent Chronic Lymphocytic Leukemia (4)

NCT	Acronym	Phase	Status	Title
NCT02160015	—	P1	active not recruiting	Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
NCT04230304	—	P2	terminated	Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
NCT03045328	—	P2	completed	Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
NCT02614508	—	P1	terminated	Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Primary Central Nervous System Lymphoma (4)

NCT	Acronym	Phase	Status	Title
NCT02203526	TEDDI-R	P1	active not recruiting	Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
NCT04421560	—	P1/P2	recruiting	Pembrolizumab, Ibrutinib and Rituximab in PCNSL
NCT04514393	—	P2	unknown	Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
NCT04066920	—	P2	unknown	IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL

Follicular Lymphoma (4)

NCT	Acronym	Phase	Status	Title
NCT02947347	—	P3	completed	Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
NCT02451111	—	P2	terminated	Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
NCT02966730	—	Early P1	terminated	Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy
NCT01980654	—	P2	completed	Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

Prolymphocytic Leukemia (4)

NCT	Acronym	Phase	Status	Title
NCT01589302	—	P2	active not recruiting	PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
NCT02007044	—	P2	active not recruiting	Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
NCT02303392	—	P1	completed	Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
NCT02662296	—	P2	withdrawn	Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Leukemia (3)

NCT	Acronym	Phase	Status	Title
NCT07052695	—	P1/P2	recruiting	Mosunetuzumab for CLL MRD Clearance
NCT02910583	Captivate	P2	completed	Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
NCT03873493	—	P2	completed	A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

Relapsing Multiple Sclerosis (3)

NCT	Acronym	Phase	Status	Title
NCT06846281	—	P3	recruiting	Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT05147220	REMODEL-1	P3	active not recruiting	Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281	REMODEL-2	P3	active not recruiting	Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Chronic Graft Versus Host Disease (3)

NCT	Acronym	Phase	Status	Title
NCT06271616	—	P2	terminated	Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
NCT03790332	—	P1/P2	completed	Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
NCT02959944	iNTEGRATE	P3	completed	Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

Waldenstrom's Macroglobulinemia (3)

NCT	Acronym	Phase	Status	Title
NCT03225716	—	P1	terminated	A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
NCT02604511	—	P2	completed	Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
NCT04274738	WM	P1	completed	A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Marginal Zone Lymphoma (3)

NCT	Acronym	Phase	Status	Title
NCT03697512	MALIBU	P2	active not recruiting	MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
NCT04212013	—	P3	active not recruiting	A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
NCT01980628	—	P2	completed	Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

Recurrent Mantle Cell Lymphoma (3)

NCT	Acronym	Phase	Status	Title
NCT02159755	—	P1	active not recruiting	Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
NCT03219047	—	Early P1	completed	Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma
NCT02736617	—	P2	completed	Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Diffuse Large B-Cell Lymphoma (3)

NCT	Acronym	Phase	Status	Title
NCT03684694	—	P1/P2	terminated	Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
NCT02692248	—	P2	completed	Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
NCT02401048	—	P1/P2	completed	A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

B-Cell Chronic Lymphocytic Leukemia (3)

NCT	Acronym	Phase	Status	Title
NCT03204188	—	P2	completed	Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT03755947	—	P2	completed	Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia
NCT02381080	CYP	P1	completed	Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

Lymphoma, Non-Hodgkin (3)

NCT	Acronym	Phase	Status	Title
NCT03310619	PLATFORM	P1/P2	completed	A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
NCT02703272	—	P3	terminated	A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
NCT02954406	—	P1	terminated	A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

Adult B Acute Lymphoblastic Leukemia (3)

NCT	Acronym	Phase	Status	Title
NCT02997761	—	P2	completed	Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
NCT02129062	—	P2	terminated	Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
NCT02109224	—	P1	terminated	Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

Multiple Myeloma (3)

NCT	Acronym	Phase	Status	Title
NCT01962792	—	P1/P2	completed	Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
NCT02902965	—	P2	completed	Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
NCT02548962	—	P1/P2	terminated	Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Primary Central Nervous System Lymphoma (PCNSL) (2)

NCT	Acronym	Phase	Status	Title
NCT07082868	CNSL	P1	recruiting	A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
NCT03703167	—	P1	completed	Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Hidradenitis Suppurativa (2)

NCT	Acronym	Phase	Status	Title
NCT06840392	RECHARGE-2	P3	active not recruiting	A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06799000	RECHARGE 1	P3	active not recruiting	A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

Chronic Spontaneous Urticaria (2)

NCT	Acronym	Phase	Status	Title
NCT06042478	—	P3	active not recruiting	Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT05170724	—	N/A	available	Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria

Chronic Graft-versus-host-disease (2)

NCT	Acronym	Phase	Status	Title
NCT05348096	—	P2	unknown	Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease
NCT03689894	—	P1/P2	terminated	Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT

DLBCL (2)

NCT	Acronym	Phase	Status	Title
NCT03731234	—	P2	active not recruiting	Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance
NCT04994626	—	P2	unknown	Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Ann Arbor Stage II Follicular Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT04450173	—	P2	active not recruiting	Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
NCT02532257	—	P2	completed	Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

Mantle Cell Lymphoma (MCL) (2)

NCT	Acronym	Phase	Status	Title
NCT04477486	—	P2	completed	Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT03877055	—	P1/P2	completed	A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

CCND1 Positive (2)

NCT	Acronym	Phase	Status	Title
NCT01880567	—	P2	active not recruiting	Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT03232307	—	P2	withdrawn	Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Diffuse Large B-cell Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT03939182	—	P1	completed	Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
NCT03876028	—	P1	terminated	Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Relapsed or Refractory Chronic Lymphocytic Leukemia (2)

NCT	Acronym	Phase	Status	Title
NCT03734198	IDA53	P2	active not recruiting	Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction
NCT01578707	RESONATE™	P3	completed	A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Mantle-Cell Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT03112174	SYMPATICO	P3	completed	Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
NCT03323151	PrE0404	P1/P2	completed	A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

B-cell Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT03424122	CITADEL-112	P1	completed	INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
NCT02055924	BIBLOS	P1	terminated	Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas

B-cell Chronic Lymphocytic Leukemia (2)

NCT	Acronym	Phase	Status	Title
NCT03088878	—	P1/P2	completed	A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
NCT02437019	EAP	N/A	approved for marketing	Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Relapsed Diffuse Large B-Cell Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT02077166	—	P1/P2	completed	Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT03136497	—	P1	terminated	A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Lymphoma, B-Cell (2)

NCT	Acronym	Phase	Status	Title
NCT03229200	—	P4	active not recruiting	Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT02670317	FIL-GALILEO	P2	terminated	Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.

Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT02973399	—	P1	terminated	Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
NCT02914327	—	P1	withdrawn	Safety and Activity of SNX-5422 Plus Ibrutinib in CLL

Metastatic Melanoma (2)

NCT	Acronym	Phase	Status	Title
NCT02581930	—	P2	active not recruiting	Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
NCT03021460	—	P1	active not recruiting	Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Waldenström's Macroglobulinemia (2)

NCT	Acronym	Phase	Status	Title
NCT03053440	ASPEN	P3	completed	A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
NCT02165397	—	P3	completed	Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

Classical Hodgkin Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT02940301	—	P2	active not recruiting	Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT02824029	—	P2	completed	Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Blastoid Variant Mantle Cell Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT02427620	—	P2	active not recruiting	Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT02869633	—	P2	completed	Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Stage I Chronic Lymphocytic Leukemia (2)

NCT	Acronym	Phase	Status	Title
NCT01886872	—	P3	active not recruiting	Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT02649387	MERIT	P2	completed	Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy

Metastatic Pancreatic Adenocarcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT02562898	—	P1/P2	completed	Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
NCT02436668	RESOLVE	P3	completed	Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Waldenstrom Macroglobulinaemia (1)

NCT	Acronym	Phase	Status	Title
NCT07474961	BLOOD-dose	P4	not yet recruiting	BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

Multiple Sclerosis (MS) - Relapsing-remitting (1)

NCT	Acronym	Phase	Status	Title
NCT07222956	RemiSeven	P2	not yet recruiting	A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

Indication of the Parent Protocol (1)

NCT	Acronym	Phase	Status	Title
NCT07456891	—	P3	recruiting	Remibrutinib Open Label Roll-over Post-trial Access Protocol

Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) (1)

NCT	Acronym	Phase	Status	Title
NCT06958705	—	P2	recruiting	Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

Secondary Progressive Multiple Sclerosis (SPMS) (1)

NCT	Acronym	Phase	Status	Title
NCT07225504	REMASTER	P3	recruiting	A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements (1)

NCT	Acronym	Phase	Status	Title
NCT06649812	—	P2	recruiting	Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Waldenström Macroglobulinemia (WM) (1)

NCT	Acronym	Phase	Status	Title
NCT07169565	—	P1	not yet recruiting	Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Autoimmune and Chronic Inflammatory Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT07032272	—	P1	completed	A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

Chronic Spontaneous Urticaria (CSU) (1)

NCT	Acronym	Phase	Status	Title
NCT06868212	RECLAIM	P3	recruiting	A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) (1)

NCT	Acronym	Phase	Status	Title
NCT06865651	LOU064	P2	recruiting	Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

Generalized Myasthenia Gravis (1)

NCT	Acronym	Phase	Status	Title
NCT06744920	RELIEVE	P3	recruiting	A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Chronic B-cell Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT06561243	—	N/A	active not recruiting	Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies

Hematological Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT06224452	—	N/A	unknown	Is Ibrutinib-related Atrial Fibrillation Dose Dependent

Non-hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05998642	—	P2	recruiting	Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Chronic Inducible Urticaria (1)

NCT	Acronym	Phase	Status	Title
NCT05976243	—	P3	active not recruiting	A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Autoimmune Hemolytic Anemia (1)

NCT	Acronym	Phase	Status	Title
NCT05694312	—	P2	recruiting	Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Mantle Cell Lymphoma Refractory (1)

NCT	Acronym	Phase	Status	Title
NCT05864742	—	P2	active not recruiting	Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Recurrent Transformed Chronic Lymphocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT05672173	—	P2	active not recruiting	Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Hepatic Impairment (1)

NCT	Acronym	Phase	Status	Title
NCT05753592	—	P1	completed	A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants

Allergy, Peanut (1)

NCT	Acronym	Phase	Status	Title
NCT05432388	—	P2	completed	Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

PCNSL (1)

NCT	Acronym	Phase	Status	Title
NCT05782374	ReWIPretro	N/A	active not recruiting	Real World Data on Ibrutinib Use in PCNSL Rel/Ref

Hematopoietic and Lymphoid Cell Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT04781855	—	P1	withdrawn	Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05283720	SC	P2	recruiting	A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS) (1)

NCT	Acronym	Phase	Status	Title
NCT05211336	VIPOR	P1	active not recruiting	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Ependymoma (1)

NCT	Acronym	Phase	Status	Title
NCT05106296	—	P1	recruiting	Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Lymphoplasmacytic Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04840602	—	P2	recruiting	Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Richter Transformation (1)

NCT	Acronym	Phase	Status	Title
NCT04992377	BDHRT001	P2	unknown	R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL

Richter's Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT04939363	—	P2	completed	A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;

Chronic GVHD (1)

NCT	Acronym	Phase	Status	Title
NCT04294641	—	P2	completed	Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Steroid Refractory GVHD (1)

NCT	Acronym	Phase	Status	Title
NCT05052385	—	N/A	completed	ECP Combination Study

Chronic Lymphoid Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT04608318	CLL17	P3	active not recruiting	Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

CLL (1)

NCT	Acronym	Phase	Status	Title
NCT04639362	—	P2	active not recruiting	CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

Asymptomatic COVID-19 Infection Laboratory-Confirmed (1)

NCT	Acronym	Phase	Status	Title
NCT04665115	COVID-19	P2	withdrawn	Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04607772	RR	P1/P2	withdrawn	Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma, Large B-Cell, Diffuse (1)

NCT	Acronym	Phase	Status	Title
NCT04446962	LOC-R01	P1/P2	active not recruiting	LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)

Aplastic Anemia (1)

NCT	Acronym	Phase	Status	Title
NCT04439006	—	P1	completed	Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT04522284	—	P1/P2	unknown	PRECISE CURATE.AI Pilot Clinical Trial

B-Cell Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT04509700	INCB050465	P2	active not recruiting	Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Small Lymphocytic Leukemia (SLL) (1)

NCT	Acronym	Phase	Status	Title
NCT04209621	—	P2	terminated	Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CoronaVirus Induced Disease-2019 (COVID-19) (1)

NCT	Acronym	Phase	Status	Title
NCT04375397	iNSPIRE	P2	completed	Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

Refractory/Relapsed Autoimmune Hemolytic Anemia (1)

NCT	Acronym	Phase	Status	Title
NCT04398459	—	P2	active not recruiting	The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Mantle Cell Lymphoma Recurrent (1)

NCT	Acronym	Phase	Status	Title
NCT04234061	TARMAC	P2	active not recruiting	Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma

Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL) (1)

NCT	Acronym	Phase	Status	Title
NCT04129710	PCNSL	P2	unknown	A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Graft Vs Host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT04235036	—	P2	terminated	Ibrutinib and Rituxan for Chronic GVHD

Intermediate Risk Chronic Lymphocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT04010968	ERADIC	P2	completed	Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

Refractory Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT03702725	—	P1	completed	Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Sjögren Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT04035668	LOUiSSe	P2	terminated	A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

Central Nervous System Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03964090	TEDDI-R	P2	active not recruiting	Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Relapsed/Refractory Chronic Lymphocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT03708003	—	P2	terminated	Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Central Nervous System B-Cell Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03770416	—	P2	completed	Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

Head and Neck Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03646461	—	P2	terminated	Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

FLT3-ITD Mutation (1)

NCT	Acronym	Phase	Status	Title
NCT03642236	—	P2/P3	unknown	Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Glioblastoma (1)

NCT	Acronym	Phase	Status	Title
NCT03535350	—	P1	active not recruiting	Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) (1)

NCT	Acronym	Phase	Status	Title
NCT03581942	PCNSL	P1/P2	completed	Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Recurrent Waldenstrom Macroglobulinemia (1)

NCT	Acronym	Phase	Status	Title
NCT03506373	—	P2	terminated	Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Metastatic Malignant Solid Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT03525925	—	P1	completed	Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic (1)

NCT	Acronym	Phase	Status	Title
NCT03207555	CLL	P2	completed	Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

Graft vs Host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT03474679	BTK	P3	completed	A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

B-Cell Prolymphocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT03479268	—	P1	active not recruiting	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

AIDS-Related Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03220022	—	P1	active not recruiting	Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Amyloidosis (1)

NCT	Acronym	Phase	Status	Title
NCT03130348	—	P2	withdrawn	Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis

Non-Hodgkin's Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03198026	—	P2	active not recruiting	Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Colon Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03332498	—	P1/P2	completed	Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

Relapsed Hematologic Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT03328078	CA-4948	P1/P2	recruiting	CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Myelodysplastic Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT03359460	—	P1	completed	Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Breast Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT03379428	—	P1/P2	active not recruiting	Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Acute Biphenotypic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT03267186	—	P2	completed	Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT03469895	CABRI	N/A	unknown	Autoimmune Cytopenia and BcR Inhibitors

Graft-versus-host Disease (GVHD) (1)

NCT	Acronym	Phase	Status	Title
NCT03112603	BAT	P3	completed	A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Chronic Lymphocytic Leukemia in Relapse (1)

NCT	Acronym	Phase	Status	Title
NCT03226301	RR-CLL	P2	active not recruiting	A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Hematopoietic/Lymphoid Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03121534	—	P2	terminated	Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

Richter Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT03145480	—	P2	terminated	Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

High Risk Smoldering Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT02943473	—	P2	terminated	Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

Food Allergy (1)

NCT	Acronym	Phase	Status	Title
NCT03149315	—	P2	completed	Inhibition of Anaphylaxis by Ibrutinib

Recurrent Plasma Cell Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT03015792	—	P1	terminated	Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

Refractory Follicular Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02956382	—	P1/P2	completed	Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

AIHA - Warm Autoimmune Hemolytic Anemia (1)

NCT	Acronym	Phase	Status	Title
NCT03827603	ISRAEL	P2	unknown	Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02950220	—	P1	completed	Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Lung Cancer, Nonsmall Cell, Stage I (1)

NCT	Acronym	Phase	Status	Title
NCT02950038	NSCLC	P2	withdrawn	Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

Recurrent Adult Acute Myeloid Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT02635074	—	P1	terminated	Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Metastatic Renal Cell Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02899078	—	P1/P2	completed	Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

Grade 1 Follicular Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02927964	—	P1/P2	completed	TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type (1)

NCT	Acronym	Phase	Status	Title
NCT02443077	—	P3	active not recruiting	Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Leukemia, Lymphocytic, Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT02758665	CLL2-GiVe	P2	completed	Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL

Acute Lymphoblastic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT02815059	—	P1	withdrawn	Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone

Nodular Lymphocyte-Predominant Hodgkin's Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02626884	IRENO	P2	completed	Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)

Prostate Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02643667	—	P2	completed	Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

Gastrooesophageal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02884453	iMYC	P2	unknown	Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma

Lymphoma, B-Cell, Marginal Zone (1)

NCT	Acronym	Phase	Status	Title
NCT03093831	—	P2	terminated	Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02780830	INHIBITOR	P1	withdrawn	AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02744612	—	P2	completed	Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Chronic Lymphoid Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT02787369	—	P1	active not recruiting	ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Chronic Myelomonocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT02553941	—	P1	completed	Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02670616	—	P2	completed	Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Indolent Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02689869	Alternative	P2	unknown	Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma

Diffuse Large B-Cell Lymphoma Unclassifiable (1)

NCT	Acronym	Phase	Status	Title
NCT02636322	—	P2	completed	Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

Metastatic Renal Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02599324	—	P1/P2	completed	Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Leukemia, Lymphoblastic, Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT02388048	—	P2	completed	Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

Carcinoid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT02575300	—	P2	completed	Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Primary Central Nervous Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02542514	iLOC	P2	completed	Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma

Lymphocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT02556892	BTK	P1	completed	A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Loss of Chromosome 17p (1)

NCT	Acronym	Phase	Status	Title
NCT02420912	—	P2	completed	Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

Hematologic Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT02352558	—	P1	completed	A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Relapsed/Refractory Mantle Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02460276	PHILEMON	P2	completed	A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02321540	EGFR	P1/P2	completed	A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

Aggressive Systemic Mastocytosis (1)

NCT	Acronym	Phase	Status	Title
NCT02415608	—	P2	terminated	Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02403271	—	P1/P2	completed	A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Hematologic Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT02329847	—	P1/P2	completed	A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies

Chronic Lymphocyte Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT02232386	LLC1114	P2	completed	Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia

Acute Myeloid Leukemia (AML) (1)

NCT	Acronym	Phase	Status	Title
NCT02351037	—	P2	terminated	Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

Recurrent B-Cell Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02332980	—	P2	completed	Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

T-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02309580	—	P1	completed	Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

Chronic Lymphocytic Leucemia (1)

NCT	Acronym	Phase	Status	Title
NCT02345863	—	P2	completed	Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

Contiguous Stage II Mantle Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02242097	—	P2	completed	Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) (1)

NCT	Acronym	Phase	Status	Title
NCT02315326	BTK	P1/P2	completed	Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02268851	—	P1	completed	A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Recurrent Transformed B-Cell Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02207062	—	P2	completed	Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

CD20 Positive (1)

NCT	Acronym	Phase	Status	Title
NCT02219737	—	P1	completed	Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Lymphoma, Mantle-cell (1)

NCT	Acronym	Phase	Status	Title
NCT02169180	BTK	P2	completed	Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Graft Versus Host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT02195869	—	P1/P2	completed	Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Diffuse Large B Cell Lymphoma Relapsed (1)

NCT	Acronym	Phase	Status	Title
NCT02142049	—	P1/P2	completed	Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Anemia (1)

NCT	Acronym	Phase	Status	Title
NCT02048813	—	P3	active not recruiting	Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT01829568	—	P1	active not recruiting	Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Hairy Cell Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT01841723	—	P2	active not recruiting	Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Recurrent B-Cell Prolymphocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT01886859	—	P1	completed	Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Grade 3a Follicular Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT01849263	—	P2	active not recruiting	Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

Chronic Lymphocytic Leukemia With 17p Deletion (1)

NCT	Acronym	Phase	Status	Title
NCT01744691	CLL	P2	completed	A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Healthy Participants (1)

NCT	Acronym	Phase	Status	Title
NCT01674322	—	P1	completed	A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants

Diffuse Large Cell B-lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT01325701	—	P2	completed	Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Relapsed or Refractory Mantle Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT01833039	—	N/A	approved for marketing	An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Ibrutinib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
BLOOD-dose	NCT07474961	P4	not yet recruiting	Waldenstrom Macroglobulinaemia	400	PMID 40049207
PCI-32765	NCT04042376	P4	completed	Waldenstrom Macroglobulinemia	17	PMID 38079089
REMASTER	NCT07225504	P3	recruiting	Secondary Progressive Multiple Sclerosis (SPMS)	1,275	—
RELIEVE	NCT06744920	P3	recruiting	Generalized Myasthenia Gravis	180	—
MK-1026	NCT06136559	P3	recruiting	Chronic Lymphocytic Leukemia	1,200	—
REMODEL-1	NCT05147220	P3	active not recruiting	Relapsing Multiple Sclerosis	1,000	—
REMODEL-2	NCT05156281	P3	active not recruiting	Relapsing Multiple Sclerosis	1,007	—
CAN3001	NCT01804686	P3	recruiting	Chronic Lymphocytic Leukemia	700	—
GLOW	NCT03462719	P3	active not recruiting	Leukemia, Lymphocytic, Chronic, B-Cell	211	PMID 37944541
BRUIN-MCL-321	NCT04662255	P3	active not recruiting	Lymphoma, Mantle-Cell	500	PMID 36377973
BRUIN-CLL-314	NCT05254743	P3	recruiting	Chronic Lymphocytic Leukemia	737	PMID 41353787
ACP-196	NCT02477696	P3	active not recruiting	Chronic Lymphocytic Leukemia	533	PMID 38754046
RECHARGE-2	NCT06840392	P3	active not recruiting	Hidradenitis Suppurativa	565	—
RECHARGE 1	NCT06799000	P3	active not recruiting	Hidradenitis Suppurativa	588	—
CLL17	NCT04608318	P3	active not recruiting	Chronic Lymphoid Leukemia	897	PMID 41358601
RECLAIM	NCT06868212	P3	recruiting	Chronic Spontaneous Urticaria (CSU)	400	PMID 41854973
SYMPATICO	NCT03112174	P3	completed	Mantle-Cell Lymphoma	366	PMID 34717692
GAIA	NCT02950051	P3	completed	Chronic Lymphocytic Leukemia	926	PMID 38821083
ALPINE	NCT03734016	P3	completed	Chronic Lymphocytic Leukemia	652	PMID 32207333
SELENE	NCT01974440	P3	completed	Lymphoma	403	PMID 37722354
BAT	NCT03112603	P3	completed	Graft-versus-host Disease (GVHD)	330	PMID 40561385
CLL12	NCT02863718	P3	completed	Chronic Lymphocytic Leukemia	515	PMID 39602678
ASPEN	NCT03053440	P3	completed	Waldenström's Macroglobulinemia	201	PMID 29869556
BTK	NCT03474679	P3	completed	Graft vs Host Disease	19	PMID 38149026
iNTEGRATE	NCT02959944	P3	completed	Chronic Graft Versus Host Disease	193	PMID 36608310
GENUINE	NCT02301156	P3	completed	Chronic Lymphocytic Leukemia	126	PMID 33631112
CLL	NCT02264574	P3	completed	Chronic Lymphocytic Leukemia	229	PMID 30522969
RESOLVE	NCT02436668	P3	completed	Metastatic Pancreatic Adenocarcinoma	430	—
RESONATE™	NCT01578707	P3	completed	Relapsed or Refractory Chronic Lymphocytic Leukemia	391	PMID 29470582
SC	NCT05283720	P2	recruiting	Non-Hodgkin Lymphoma	496	—
CARMAN	NCT06482684	P2	recruiting	Mantle Cell Lymphoma	150	PMID 40517546
Benefit VA	NCT06520098	P2	recruiting	Chronic Lymphocytic Leukemia	100	—
RemiSeven	NCT07222956	P2	not yet recruiting	Multiple Sclerosis (MS) - Relapsing-remitting	20	—
TARMAC	NCT04234061	P2	active not recruiting	Mantle Cell Lymphoma Recurrent	20	PMID 37883795
TAILOR	NCT05963074	P2	recruiting	Leukemia, Lymphocytic, Chronic, B-Cell	320	—
TEDDI-R	NCT03964090	P2	active not recruiting	Central Nervous System Lymphoma	48	—
CZAR-1	NCT04263480	P2	active not recruiting	Waldenstrom Macroglobulinemia	99	—
VALUABLE	NCT04758975	P2	recruiting	Chronic Lymphocytic Leukemia (CLL)	55	—
BDHCLL001	NCT03980002	P2	recruiting	Chronic Lymphocytic Leukemia	50	PMID 41497516
INCB050465	NCT04509700	P2	active not recruiting	B-Cell Malignancies	112	—
LOU064	NCT06865651	P2	recruiting	Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)	44	—
FIGHT	NCT04908228	P2	recruiting	Chronic Lymphocytic Leukemia	53	—
MALIBU	NCT03697512	P2	active not recruiting	Marginal Zone Lymphoma	175	PMID 40550489
iFCR	NCT02251548	P2	active not recruiting	Chronic Lymphocytic Leukemia	85	PMID 31208944
RR-CLL	NCT03226301	P2	active not recruiting	Chronic Lymphocytic Leukemia in Relapse	230	PMID 40249856
MERIT	NCT02649387	P2	completed	Stage I Chronic Lymphocytic Leukemia	35	—
PCNSL	NCT04129710	P2	unknown	Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)	120	—
IDA53	NCT03734198	P2	active not recruiting	Relapsed or Refractory Chronic Lymphocytic Leukemia	29	—
IV	NCT05105841	P2	completed	Chronic Lymphocytic Leukemia (CLL)	20	—
BDHRT001	NCT04992377	P2	unknown	Richter Transformation	30	—
AIM	NCT02471391	P2	unknown	Mantle Cell Lymphoma	37	PMID 29590547
ERADIC	NCT04010968	P2	completed	Intermediate Risk Chronic Lymphocytic Leukemia	120	—
VEGA	NCT05564052	P2	completed	Lymphoma, Mantle-Cell	36	—
CLL	NCT03207555	P2	completed	Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic	23	—
LLC1114	NCT02232386	P2	completed	Chronic Lymphocyte Leukemia	156	PMID 35913400
Captivate	NCT02910583	P2	completed	Leukemia	323	PMID 34618601
R-CHOEP-brut	NCT03399513	P2	completed	Diffuse Large B Cell Lymphoma	40	—
ICLL07GAI	NCT02666898	P2	completed	Leukemia, Lymphocytic, Chronic, B-Cell	135	PMID 37026799
WM	NCT04062448	P2	completed	Waldenstrom Macroglobulinemia	16	—
Alternative	NCT02689869	P2	unknown	Indolent Non-Hodgkin Lymphoma	98	—
COVID-19	NCT04665115	P2	withdrawn	Asymptomatic COVID-19 Infection Laboratory-Confirmed	0	—
CLL	NCT04016805	P2	terminated	Chronic Lymphocytic Leukemia	41	—
ISRAEL	NCT03827603	P2	unknown	AIHA - Warm Autoimmune Hemolytic Anemia	50	—
CLL2-GiVe	NCT02758665	P2	completed	Leukemia, Lymphocytic, Chronic	41	—
iMYC	NCT02884453	P2	unknown	Gastrooesophageal Cancer	17	PMID 28830912
iLOC	NCT02542514	P2	completed	Primary Central Nervous Lymphoma	52	PMID 31279304
LOUiSSe	NCT04035668	P2	terminated	Sjögren Syndrome	73	PMID 37932009
iNSPIRE	NCT04375397	P2	completed	CoronaVirus Induced Disease-2019 (COVID-19)	46	PMID 35493119
IRENO	NCT02626884	P2	completed	Nodular Lymphocyte-Predominant Hodgkin's Lymphoma	14	—
CLL2-BIO	NCT02689141	P2	completed	Chronic Lymphocytic Leukemia	66	PMID 32107341
PHILEMON	NCT02460276	P2	completed	Relapsed/Refractory Mantle Cell Lymphoma	50	PMID 29396091
SCT	NCT02272686	P2	terminated	Lymphoma	1	—
FIL-GALILEO	NCT02670317	P2	terminated	Lymphoma, B-Cell	1	—
NSCLC	NCT02950038	P2	withdrawn	Lung Cancer, Nonsmall Cell, Stage I	0	—
BTK	NCT02169180	P2	completed	Lymphoma, Mantle-cell	16	PMID 27616553
CLL	NCT01744691	P2	completed	Chronic Lymphocytic Leukemia With 17p Deletion	145	PMID 27637985

Terminated and withdrawn Ibrutinib trials (61)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT03617484withdrawnBortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
NCT04685915withdrawnCopanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
NCT05431179withdrawnA Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT06271616terminatedIbrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
NCT03506373terminatedIbrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
NCT04607772withdrawnStudy of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
NCT03708003terminatedIbrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
NCT04781855withdrawnIpilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
NCT04230304terminatedDaratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
NCT03400176terminatedVAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib
NCT02451111terminatedRituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
NCT03514017terminatedIbrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
NCT03225716terminatedA Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
NCT04235036terminatedIbrutinib and Rituxan for Chronic GVHD
NCT03684694terminatedSafety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
NCT03015792terminatedIbrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
NCT04665115withdrawnIbrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
NCT04016805terminatedStudy to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
NCT03130348withdrawnIbrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis
NCT03121534terminatedIbrutinib, Nivolumab and Blinatumomab in Richter Transformation
NCT04035668terminatedA Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
NCT03876028terminatedStudy of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
NCT03689894terminatedIbrutinib Plus Rituximab for cGVHD Following Allo-SCT
NCT03943342withdrawnIbrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
NCT03232307withdrawnIbrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
NCT02703272terminatedA Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
NCT03646461terminatedTrial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
NCT01644253terminatedPhase 1b Safety and Efficacy Study of TRU-016
NCT02356458terminatedCombination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
NCT04209621terminatedDuvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT02611908withdrawnObinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
NCT03136497terminatedA Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT03679624terminatedDaratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
NCT02954406terminatedA Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
NCT03093831terminatedPhase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
NCT02743546withdrawnStudy of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
NCT04043845withdrawnERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
NCT03572634terminatedPhase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
NCT02943473terminatedStudy on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
NCT02614508terminatedBuparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT02966730terminatedIbrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy
NCT02780830withdrawnAZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02973399terminatedEfficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
NCT02677948withdrawnMulticenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT02055924terminatedBruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
NCT03145480terminatedStudy of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients
NCT02914327withdrawnSafety and Activity of SNX-5422 Plus Ibrutinib in CLL
NCT02548962terminatedStudy of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
NCT02269085terminatedTrial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
NCT02815059withdrawnStudy of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
NCT02272686terminatedIbrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
NCT02635074terminatedIbrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02200848terminatedPhase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
NCT02415608terminatedIbrutinib in Treating Patients With Advanced Systemic Mastocytosis
NCT02351037terminatedStudy of Ibrutinib in Subjects With Acute Myeloid Leukemia
NCT02670317terminatedPhase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.
NCT02950038withdrawnStudy of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
NCT02735876withdrawnA Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
NCT02662296withdrawnIbrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
NCT02129062terminatedIbrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
NCT02109224terminatedIbrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

All Ibrutinib trials (352)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT07474961	BLOOD-dose	BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.	P4	not yet recruiting	400	Anne Louise Tølbøll Sørensen	Mar 2027
NCT04446962	LOC-R01	LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)	P1/P2	active not recruiting	118	Institut Curie	Oct 2020
NCT02514083		A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL	P2	active not recruiting	29	National Heart, Lung, and Blood Institute (NHLBI)	Dec 2015
NCT07225504	REMASTER	A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis	P3	recruiting	1,275	Novartis Pharmaceuticals	Nov 2025
NCT06744920	RELIEVE	A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis	P3	recruiting	180	Novartis Pharmaceuticals	Feb 2025
NCT07456891		Remibrutinib Open Label Roll-over Post-trial Access Protocol	P3	recruiting	212	Novartis Pharmaceuticals	Apr 2026
NCT07377578		A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma	P3	recruiting	394	Guangzhou Lupeng Pharmaceutical Company LTD.	Feb 2026
NCT07052695		Mosunetuzumab for CLL MRD Clearance	P1/P2	recruiting	40	Inhye Ahn	Nov 2025
NCT05283720	SC	A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma	P2	recruiting	496	Genmab	Jun 2022
NCT06136559	MK-1026	A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)	P3	recruiting	1,200	Merck Sharp & Dohme LLC	Dec 2023
NCT03198026		Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas	P2	active not recruiting	30	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Feb 2018
NCT06482684	CARMAN	CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma	P2	recruiting	150	Christian Schmidt, MD	Feb 2024
NCT04802590		Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma	P2	active not recruiting	210	The Lymphoma Academic Research Organisation	Jan 2022
NCT06846281		Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.	P3	recruiting	360	Novartis Pharmaceuticals	Jul 2025
NCT04739813		Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma	P1	active not recruiting	34	National Cancer Institute (NCI)	Jul 2021
NCT06520098	Benefit VA	A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	P2	recruiting	100	VA Office of Research and Development	Oct 2025
NCT07222956	RemiSeven	A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS	P2	not yet recruiting	20	Moein Amin	Jun 2026
NCT05147220	REMODEL-1	Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)	P3	active not recruiting	1,000	Novartis Pharmaceuticals	Dec 2021
NCT05156281	REMODEL-2	Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)	P3	active not recruiting	1,007	Novartis Pharmaceuticals	Dec 2021
NCT04234061	TARMAC	Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma	P2	active not recruiting	20	Peter MacCallum Cancer Centre, Australia	Apr 2020
NCT03617484		Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma	P2	withdrawn	0	University of Michigan Rogel Cancer Center	Jul 2020
NCT04061512	RAINBOW	Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia	P2/P3	recruiting	148	University College, London	Feb 2020
NCT02682641		Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL	P2	active not recruiting	50	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	May 2016
NCT01804686	CAN3001	A Long-term Extension Study of PCI-32765 (Ibrutinib)	P3	recruiting	700	Janssen Research & Development, LLC	Sep 2013
NCT01841723		Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia	P2	active not recruiting	44	National Cancer Institute (NCI)	Apr 2013
NCT06357676		Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial	P1/P2	recruiting	27	OHSU Knight Cancer Institute	May 2025
NCT05976243		A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines	P3	active not recruiting	362	Novartis Pharmaceuticals	Dec 2023
NCT05864742		Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma	P2	active not recruiting	40	Peter MacCallum Cancer Centre, Australia	Sep 2023
NCT05211336	VIPOR	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System	P1	active not recruiting	14	National Cancer Institute (NCI)	Apr 2022
NCT03462719	GLOW	A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	P3	active not recruiting	211	Janssen Research & Development, LLC	Apr 2018
NCT05963074	TAILOR	A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia	P2	recruiting	320	Janssen Research & Development, LLC	May 2024
NCT05998642		Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma	P2	recruiting	30	Canadian Cancer Trials Group	Feb 2024
NCT04639362		CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.	P2	active not recruiting	85	Stichting Hemato-Oncologie voor Volwassenen Nederland	Dec 2020
NCT05106296		Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer	P1	recruiting	37	Theodore S. Johnson	Feb 2022
NCT07169565		Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia	P1	not yet recruiting	21	Institute of Hematology & Blood Diseases Hospital, China	Sep 2025
NCT07082868	CNSL	A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)	P1	recruiting	26	Memorial Sloan Kettering Cancer Center	Aug 2025
NCT03422393		Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib	P1	active not recruiting	24	Michael Choi	May 2018
NCT03964090	TEDDI-R	Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)	P2	active not recruiting	48	National Cancer Institute (NCI)	Jun 2019
NCT04263480	CZAR-1	Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia	P2	active not recruiting	99	Christian Buske	Aug 2021
NCT03960840		Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL	P1/P2	active not recruiting	217	Novartis Pharmaceuticals	Jun 2019
NCT03701282		Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia	P3	active not recruiting	720	National Cancer Institute (NCI)	Feb 2019
NCT04662255	BRUIN-MCL-321	Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)	P3	active not recruiting	500	Loxo Oncology, Inc.	Apr 2021
NCT04840602		Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma	P2	recruiting	92	National Cancer Institute (NCI)	Jan 2022
NCT02629809		Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia	P2	active not recruiting	81	M.D. Anderson Cancer Center	Mar 2016
NCT04685915		Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL	P2	withdrawn	0	Inhye Ahn	Feb 2021
NCT03282396		Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma	P2	active not recruiting	20	M.D. Anderson Cancer Center	Jun 2020
NCT06958705		Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy	P2	recruiting	79	The First Affiliated Hospital with Nanjing Medical University	Dec 2025
NCT04273139		Ibrutinib + Venetoclax in Untreated WM	P2	active not recruiting	45	Dana-Farber Cancer Institute	Jul 2020
NCT05254743	BRUIN-CLL-314	A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	P3	recruiting	737	Loxo Oncology, Inc.	Jul 2022
NCT02477696	ACP-196	Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)	P3	active not recruiting	533	Acerta Pharma BV	Jul 2015
NCT04758975	VALUABLE	Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)	P2	recruiting	55	Paolo Ghia	Sep 2022
NCT03980002	BDHCLL001	A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL	P2	recruiting	50	Institute of Hematology & Blood Diseases Hospital, China	May 2019
NCT04771507	IbruOnOff	A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)	P1/P2	recruiting	50	Jeanette Lundin	Feb 2018
NCT03223610		Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma	P1/P2	recruiting	155	National Cancer Institute (NCI)	Feb 2018
NCT02203526	TEDDI-R	Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma	P1	active not recruiting	68	National Cancer Institute (NCI)	Aug 2014
NCT03331198	CLL	Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)	P1/P2	recruiting	320	Juno Therapeutics, a Subsidiary of Celgene	Nov 2017
NCT06536049		Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma	P1/P2	recruiting	38	Yazeed Sawalha	Apr 2025
NCT06299540	QOLIBRI	Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia	—	recruiting	180	Janssen Cilag S.A.S.	May 2024
NCT06840392	RECHARGE-2	A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa	P3	active not recruiting	565	Novartis Pharmaceuticals	Mar 2025
NCT06799000	RECHARGE 1	A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)	P3	active not recruiting	588	Novartis Pharmaceuticals	Jan 2025
NCT04608318	CLL17	Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)	P3	active not recruiting	897	German CLL Study Group	Mar 2021
NCT04509700	INCB050465	Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)	P2	active not recruiting	112	Incyte Corporation	Aug 2020
NCT06865651	LOU064	Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria	P2	recruiting	44	Novartis Pharmaceuticals	May 2025
NCT04908228	FIGHT	Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL	P2	recruiting	53	Paolo Ghia	Dec 2021
NCT06649812		Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma	P2	recruiting	120	National Cancer Institute (NCI)	Oct 2025
NCT03731234		Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance	P2	active not recruiting	75	Fondazione Italiana Linfomi - ETS	Jul 2019
NCT06042478		Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.	P3	active not recruiting	470	Novartis Pharmaceuticals	Nov 2023
NCT02756897		Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia	P2	active not recruiting	234	M.D. Anderson Cancer Center	Jul 2016
NCT02427620		Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma	P2	active not recruiting	131	M.D. Anderson Cancer Center	Jun 2015
NCT03697512	MALIBU	MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas	P2	active not recruiting	175	International Extranodal Lymphoma Study Group (IELSG)	Sep 2019
NCT03128879		Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL	P2	recruiting	90	M.D. Anderson Cancer Center	Jun 2017
NCT06868212	RECLAIM	A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines	P3	recruiting	400	Novartis Pharmaceuticals	Jul 2025
NCT03229200		Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.	P4	active not recruiting	297	Pharmacyclics Switzerland GmbH	May 2017
NCT01955499		Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	P1	active not recruiting	39	National Cancer Institute (NCI)	Sep 2013
NCT04450173		Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma	P2	active not recruiting	40	University of California, Davis	Feb 2021
NCT02787369		ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL	P1	active not recruiting	3	Dana-Farber Cancer Institute	May 2016
NCT02159755		Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma	P1	active not recruiting	28	National Cancer Institute (NCI)	Aug 2014
NCT02427451		Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia	P1/P2	active not recruiting	87	Kerry Rogers	Aug 2015
NCT03710772		Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma	P2	active not recruiting	51	M.D. Anderson Cancer Center	May 2019
NCT01849263		Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma	P2	active not recruiting	41	National Cancer Institute (NCI)	Apr 2013
NCT04212013		A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma	P3	active not recruiting	23	Memorial Sloan Kettering Cancer Center	Dec 2019
NCT02581930		Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma	P2	active not recruiting	18	National Cancer Institute (NCI)	Aug 2016
NCT03620903		Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia	P2	active not recruiting	53	Christian Buske	Sep 2019
NCT02537613		A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	P1	active not recruiting	54	Dana-Farber Cancer Institute	Dec 2015
NCT02251548	iFCR	A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia	P2	active not recruiting	85	Dana-Farber Cancer Institute	Oct 2014
NCT04421560		Pembrolizumab, Ibrutinib and Rituximab in PCNSL	P1/P2	recruiting	37	Dana-Farber Cancer Institute	Aug 2020
NCT05431179		A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma	P3	withdrawn	0	Oncternal Therapeutics, Inc	Mar 2023
NCT03513562		Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations	P2	active not recruiting	28	Ohio State University Comprehensive Cancer Center	Mar 2019
NCT03021460		Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery	P1	active not recruiting	20	Mayo Clinic	Jan 2017
NCT02436707		Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma	P2	active not recruiting	129	Canadian Cancer Trials Group	Oct 2015
NCT03737981		Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia	P3	active not recruiting	465	National Cancer Institute (NCI)	Jan 2019
NCT02443077		Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma	P3	active not recruiting	94	National Cancer Institute (NCI)	Oct 2016
NCT05694312		Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL	P2	recruiting	45	Gruppo Italiano Malattie EMatologiche dell'Adulto	Nov 2023
NCT03153202	CLL	Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)	P1/P2	active not recruiting	23	Joshua Brody	Jul 2017
NCT03479268		Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	P1	active not recruiting	18	City of Hope Medical Center	Apr 2018
NCT03328078	CA-4948	CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)	P1/P2	recruiting	152	Curis, Inc.	Dec 2017
NCT01589302		PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia	P2	active not recruiting	154	Kami Maddocks, MD	May 2012
NCT02048813		Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	P3	active not recruiting	529	National Cancer Institute (NCI)	Mar 2014
NCT05672173		Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation	P2	active not recruiting	9	City of Hope Medical Center	Jun 2023
NCT03478514		Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma	P2	active not recruiting	39	Alliance Foundation Trials, LLC.	Sep 2018
NCT02940301		Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	P2	active not recruiting	18	Ohio State University Comprehensive Cancer Center	Dec 2016
NCT02160015		Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery	P1	active not recruiting	12	National Cancer Institute (NCI)	May 2014
NCT05782374	ReWIPretro	Real World Data on Ibrutinib Use in PCNSL Rel/Ref	—	active not recruiting	36	IRCCS San Raffaele	Aug 2022
NCT02446236		Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma	P1	active not recruiting	27	Hackensack Meridian Health	Jun 2015
NCT01880567		Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma	P2	active not recruiting	113	M.D. Anderson Cancer Center	Jul 2013
NCT03220022		Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas	P1	active not recruiting	46	National Cancer Institute (NCI)	Mar 2018
NCT02007044		Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia	P2	active not recruiting	66	M.D. Anderson Cancer Center	Dec 2013
NCT03226301	RR-CLL	A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations	P2	active not recruiting	230	Stichting Hemato-Oncologie voor Volwassenen Nederland	Jun 2017
NCT01886872		Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia	P3	active not recruiting	547	National Cancer Institute (NCI)	Jan 2014
NCT01829568		Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma	P1	active not recruiting	33	National Cancer Institute (NCI)	Jun 2013
NCT02858258		ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma	P3	unknown	870	Prof. Dr. M. Dreyling (co-chairman)	Jul 2016
NCT03447808		Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia	P1	completed	15	Jennifer Woyach	Aug 2018
NCT06271616		Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant	P2	terminated	2	Mayo Clinic	Dec 2024
NCT03581942	PCNSL	Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)	P1/P2	completed	18	Memorial Sloan Kettering Cancer Center	Aug 2018
NCT03506373		Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia	P2	terminated	21	Mayo Clinic	Aug 2018
NCT02315326	BTK	Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)	P1/P2	completed	93	Memorial Sloan Kettering Cancer Center	Dec 2014
NCT03703167		Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)	P1	completed	25	Memorial Sloan Kettering Cancer Center	Jan 2019
NCT02649387	MERIT	Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy	P2	completed	35	Mayo Clinic	Feb 2016
NCT03204188		Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	P2	completed	15	National Heart, Lung, and Blood Institute (NHLBI)	Sep 2017
NCT02518555		Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	P2	completed	42	Jennifer Woyach	Jan 2016
NCT04607772	RR	Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)	P1/P2	withdrawn	0	Karyopharm Therapeutics Inc	Nov 2020
NCT04494503		Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL	P1/P2	recruiting	123	Ascentage Pharma Group Inc.	Aug 2020
NCT04129710	PCNSL	A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)	P2	unknown	120	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jan 2020
NCT03535350		Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma	P1	active not recruiting	36	Case Comprehensive Cancer Center	Aug 2018
NCT03734198	IDA53	Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction	P2	active not recruiting	29	French Innovative Leukemia Organisation	Dec 2018
NCT03708003		Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL	P2	terminated	30	Swiss Cancer Institute	Mar 2019
NCT07032272		A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.	P1	completed	16	Novartis Pharmaceuticals	Jul 2025
NCT05105841	IV	Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	P2	completed	20	AbbVie	Nov 2021
NCT03790332		Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)	P1/P2	completed	59	Pharmacyclics LLC.	Nov 2018
NCT04992377	BDHRT001	R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL	P2	unknown	30	Institute of Hematology & Blood Diseases Hospital, China	Aug 2021
NCT02997761		Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia	P2	completed	19	University of California, Davis	Jun 2017
NCT04994626		Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies	P2	unknown	20	Chinese Academy of Medical Sciences	Oct 2021
NCT04398459		The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia	P2	active not recruiting	18	Institute of Hematology & Blood Diseases Hospital, China	May 2020
NCT02471391	AIM	ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)	P2	unknown	37	Peter MacCallum Cancer Centre, Australia	Jul 2015
NCT02947347		Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma	P3	completed	445	Pharmacyclics LLC.	Jan 2017
NCT04477486		Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma	P2	completed	13	AbbVie	Sep 2020
NCT02558816	OAsIs	A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients	P1/P2	completed	48	Nantes University Hospital	Oct 2015
NCT03939182		Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma	P1	completed	15	Memorial Sloan Kettering Cancer Center	May 2019
NCT05432388		Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts	P2	completed	76	Novartis Pharmaceuticals	Oct 2022
NCT04781855		Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation	P1	withdrawn	0	M.D. Anderson Cancer Center	Jul 2022
NCT04876092		A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL	P1	completed	45	Janssen Research & Development, LLC	Jul 2021
NCT04230304		Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study	P2	terminated	8	Mayo Clinic	Nov 2020
NCT03770416		Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma	P2	completed	18	M.D. Anderson Cancer Center	Feb 2019
NCT03379428		Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer	P1/P2	active not recruiting	34	US Oncology Research	Nov 2017
NCT04010968	ERADIC	Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia	P2	completed	120	French Innovative Leukemia Organisation	Sep 2019
NCT02824029		Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	P2	completed	28	Barbara Ann Karmanos Cancer Institute	Jun 2016
NCT04939363		A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;	P2	completed	12	Bnai Zion Medical Center	Aug 2021
NCT03129828	ImbruVeRCHOP	Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2	P1/P2	completed	38	Prof. Dr. Clemens Schmitt	Mar 2017
NCT06561243		Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies	—	active not recruiting	15,000	University Hospital, Caen	Jul 2024
NCT03702725		Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma	P1	completed	14	Alliance Foundation Trials, LLC.	Aug 2019
NCT04294641		Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease	P2	completed	10	National Cancer Institute (NCI)	May 2021
NCT05564052	VEGA	A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma	P2	completed	36	Janssen Research & Development, LLC	Dec 2022
NCT03088878		A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies	P1/P2	completed	95	Oncternal Therapeutics, Inc	Jan 2018
NCT03207555	CLL	Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)	P2	completed	23	M.D. Anderson Cancer Center	May 2018
NCT02744612		Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	P2	completed	39	City of Hope Medical Center	Jun 2016
NCT06224452		Is Ibrutinib-related Atrial Fibrillation Dose Dependent	—	unknown	18,000	University Hospital, Caen	Mar 2024
NCT03112174	SYMPATICO	Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)	P3	completed	366	Pharmacyclics LLC.	Jun 2017
NCT03440567		Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma	P1	completed	16	City of Hope Medical Center	Apr 2018
NCT01776840		A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma	P3	completed	523	Janssen Research & Development, LLC	May 2013
NCT04514393		Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma	P2	unknown	33	Huiqiang Huang	Oct 2020
NCT02827617		Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia	—	completed	56	Oncology Institute of Southern Switzerland	Jun 2016
NCT02232386	LLC1114	Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia	P2	completed	156	Gruppo Italiano Malattie EMatologiche dell'Adulto	Mar 2015
NCT02388048		Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia	P2	completed	19	Gruppo Italiano Malattie EMatologiche dell'Adulto	Oct 2015
NCT02910583	Captivate	Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)	P2	completed	323	Pharmacyclics LLC.	Sep 2016
NCT04042376	PCI-32765	A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)	P4	completed	17	Janssen Research & Development, LLC	Dec 2019
NCT02956382		Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma	P1/P2	completed	24	Georgetown University	Mar 2017
NCT02950051	GAIA	Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation	P3	completed	926	German CLL Study Group	Dec 2016
NCT03734016	ALPINE	A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia	P3	completed	652	BeiGene	Nov 2018
NCT03295240		The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma	Early P1	completed	10	Memorial Sloan Kettering Cancer Center	Sep 2017
NCT03399513	R-CHOEP-brut	Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma	P2	completed	40	University Hospital Muenster	May 2018
NCT05753592		A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants	P1	completed	38	Novartis Pharmaceuticals	Oct 2022
NCT02207062		Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma	P2	completed	20	University of Washington	Oct 2014
NCT02869633		Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	P2	completed	23	Vanderbilt-Ingram Cancer Center	Nov 2016
NCT04066920		IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL	P2	unknown	30	Deok-Hwan Yang	Oct 2019
NCT03642236		Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML	P2/P3	unknown	122	Nanfang Hospital, Southern Medical University	Aug 2018
NCT02666898	ICLL07GAI	Phase II Trial GA101 Inbrutinib B CLL	P2	completed	135	French Innovative Leukemia Organisation	Oct 2015
NCT03400176		VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib	P1	terminated	39	Novartis Pharmaceuticals	Apr 2018
NCT03323151	PrE0404	A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma	P1/P2	completed	43	PrECOG, LLC.	Aug 2018
NCT02955628		RICE-ibrutinib in Relapsed DLBCL	P2	unknown	34	Singapore General Hospital	Dec 2016
NCT01724346		Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	P3	completed	269	Pharmacyclics LLC.	Dec 2013
NCT02532257		Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma	P2	completed	48	M.D. Anderson Cancer Center	Apr 2016
NCT05348096		Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease	P2	unknown	13	Hospital Universitario Dr. Jose E. Gonzalez	Apr 2022
NCT04522284		PRECISE CURATE.AI Pilot Clinical Trial	P1/P2	unknown	20	National University Hospital, Singapore	Aug 2020
NCT02451111		Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma	P2	terminated	190	Swiss Cancer Institute	Nov 2015
NCT03219047		Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma	Early P1	completed	1	M.D. Anderson Cancer Center	Dec 2018
NCT01974440	SELENE	A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma	P3	completed	403	Janssen Research & Development, LLC	Jan 2014
NCT04025593		Biomarker Guided Treatment in DLBCL	P2	unknown	128	Ruijin Hospital	Jul 2019
NCT02927964		TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma	P1/P2	completed	21	Robert Lowsky	Nov 2016
NCT03514017		Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia	P2	terminated	5	H. Lee Moffitt Cancer Center and Research Institute	May 2019
NCT02309580		Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma	P1	completed	14	Memorial Sloan Kettering Cancer Center	Jan 2015
NCT03190330		A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion	P4	completed	75	Johnson & Johnson Private Limited	Jun 2019
NCT02643667		Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer	P2	completed	27	Washington University School of Medicine	Jul 2016
NCT04062448	WM	A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)	P2	completed	16	Janssen Pharmaceutical K.K.	Sep 2019
NCT03310619	PLATFORM	A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies	P1/P2	completed	62	Celgene	Dec 2017
NCT02242097		Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma	P2	completed	37	Northwestern University	Jan 2015
NCT03225716		A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia	P1	terminated	13	Dana-Farber Cancer Institute	Oct 2017
NCT04235036		Ibrutinib and Rituxan for Chronic GVHD	P2	terminated	15	Northside Hospital, Inc.	Dec 2019
NCT03112603	BAT	A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)	P3	completed	330	Incyte Corporation	Jun 2017
NCT03684694		Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma	P1/P2	terminated	136	ADC Therapeutics S.A.	Dec 2018
NCT02604511		Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing	P2	completed	31	Dana-Farber Cancer Institute	Jan 2016
NCT04274738	WM	A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4	P1	completed	16	X4 Pharmaceuticals	Apr 2020
NCT02268851		A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL	P1	completed	45	Dana-Farber Cancer Institute	Nov 2014
NCT02636322		Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib	P2	completed	60	M.D. Anderson Cancer Center	Mar 2016
NCT03015792		Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant	P1	terminated	18	Mayo Clinic	Mar 2017
NCT03877055		A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma	P1/P2	completed	8	Memorial Sloan Kettering Cancer Center	Mar 2019
NCT02756247		A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma	P1	completed	37	Memorial Sloan Kettering Cancer Center	May 2016
NCT03280160		Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab	P2	unknown	84	PETHEMA Foundation	Sep 2017
NCT01886859		Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	P1	completed	27	National Cancer Institute (NCI)	Apr 2013
NCT04439006		Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization	P1	completed	10	Jennifer Woyach	Oct 2020
NCT02733042	FUSION NHL 001	A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia	P1/P2	completed	106	Celgene	May 2016
NCT03425591	FIRE	A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice	—	completed	508	Janssen-Cilag Ltd.	May 2016
NCT03525925		Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors	P1	completed	16	Ohio State University Comprehensive Cancer Center	Jul 2018
NCT02689869	Alternative	Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma	P2	unknown	98	Ludwig-Maximilians - University of Munich	Apr 2016
NCT04665115	COVID-19	Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)	P2	withdrawn	0	Academic and Community Cancer Research United	Nov 2020
NCT02863718	CLL12	Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression	P3	completed	515	German CLL Study Group	Apr 2014
NCT03424122	CITADEL-112	INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)	P1	completed	50	Incyte Corporation	Jul 2018
NCT03053440	ASPEN	A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)	P3	completed	201	BeiGene	Jan 2017
NCT05052385		ECP Combination Study	—	completed	319	European Society for Blood and Marrow Transplantation	Apr 2021
NCT02760485	INCB039110	A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	P1/P2	completed	33	Incyte Corporation	Dec 2016
NCT03949062		Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL	P2	unknown	30	Ruijin Hospital	Mar 2019
NCT04016805	CLL	Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax	P2	terminated	41	TG Therapeutics, Inc.	Aug 2019
NCT03130348		Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis	P2	withdrawn	0	Mayo Clinic	Mar 2018
NCT02315768	CLL	Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.	P1/P2	completed	32	University of California, San Diego	Aug 2015
NCT02303392		Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma	P1	completed	34	Jennifer Woyach	Jun 2015
NCT03827603	ISRAEL	Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia	P2	unknown	50	Eugene Nikitin	Feb 2017
NCT02758665	CLL2-GiVe	Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL	P2	completed	41	University of Ulm	Sep 2016
NCT02420912		Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation	P2	completed	37	M.D. Anderson Cancer Center	Jun 2015
NCT03121534		Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation	P2	terminated	9	M.D. Anderson Cancer Center	Jun 2017
NCT02329847		A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies	P1/P2	completed	144	Janssen Research & Development, LLC	Mar 2015
NCT02332980		Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	P2	completed	65	Mayo Clinic	Feb 2015
NCT04094051		Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice	—	unknown	580	The First Affiliated Hospital with Nanjing Medical University	Oct 2019
NCT02884453	iMYC	Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma	P2	unknown	17	Royal Marsden NHS Foundation Trust	Jul 2016
NCT05170724		Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria	—	available	0	Novartis Pharmaceuticals	—
NCT02542514	iLOC	Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma	P2	completed	52	The Lymphoma Academic Research Organisation	Sep 2015
NCT03474679	BTK	A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)	P3	completed	19	Janssen Pharmaceutical K.K.	May 2018
NCT04035668	LOUiSSe	A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome	P2	terminated	73	Novartis Pharmaceuticals	Jul 2019
NCT03720561	EVIdeNCE	A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting	—	completed	312	Janssen-Cilag S.p.A.	Oct 2018
NCT03873493		A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia	P2	completed	14	AbbVie	Jan 2020
NCT03876028		Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients	P1	terminated	10	Novartis Pharmaceuticals	Jun 2019
NCT03689894		Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT	P1/P2	terminated	2	Dartmouth-Hitchcock Medical Center	Apr 2019
NCT02321540	EGFR	A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer	P1/P2	completed	13	M.D. Anderson Cancer Center	Mar 2015
NCT03332498		Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers	P1/P2	completed	40	H. Lee Moffitt Cancer Center and Research Institute	Jan 2018
NCT02599324		Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors	P1/P2	completed	263	Pharmacyclics LLC.	Dec 2015
NCT03045328		Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL	P2	completed	22	Steven E. Coutre	Sep 2017
NCT03943342		Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance	P2	withdrawn	0	Kerry Rogers	Mar 2020
NCT02959944	iNTEGRATE	Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)	P3	completed	193	Pharmacyclics LLC.	May 2017
NCT03232307		Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma	P2	withdrawn	0	M.D. Anderson Cancer Center	Jul 2019
NCT02991638		Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers	P3	unknown	62	The University of Hong Kong	Nov 2016
NCT02703272		A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma	P3	terminated	72	Janssen Research & Development, LLC	Jul 2016
NCT04375397	iNSPIRE	Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury	P2	completed	46	AbbVie	Jun 2020
NCT02736617		Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma	P2	completed	10	OHSU Knight Cancer Institute	Jul 2016
NCT02419560		Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL	P1	completed	37	Craig Portell, MD	Apr 2015
NCT03646461		Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC	P2	terminated	5	University of California, San Diego	Oct 2018
NCT03267186		Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant	P2	completed	8	Andrew Rezvani	Sep 2017
NCT01644253		Phase 1b Safety and Efficacy Study of TRU-016	P1	terminated	87	Aptevo Therapeutics	Sep 2012
NCT02356458		Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma	P1/P2	terminated	58	Swiss Cancer Institute	Aug 2015
NCT02899078		Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer	P1/P2	completed	31	University of California, Davis	Nov 2016
NCT03755947		Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia	P2	completed	3	Grupo Cooperativo de Hemopatías Malignas	Dec 2018
NCT04209621		Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	P2	terminated	3	National Heart, Lung, and Blood Institute (NHLBI)	Jul 2020
NCT02692248		Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT	P2	completed	64	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Apr 2016
NCT03454165		A Study of BNC105P Combined With Ibrutinib	P1	completed	6	Dartmouth-Hitchcock Medical Center	Mar 2018
NCT02077166		Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	P1/P2	completed	138	Pharmacyclics LLC.	Mar 2014
NCT02611908		Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.	P1	withdrawn	0	Michael Choi	Jun 2016
NCT03136497		A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	P1	terminated	10	Hackensack Meridian Health	Sep 2017
NCT02670616		Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma	P2	completed	24	Samsung Medical Center	May 2016
NCT03679624		Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia	P2	terminated	1	Weill Medical College of Cornell University	Jul 2020
NCT02562898		Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer	P1/P2	completed	18	Margaret Tempero	Oct 2015
NCT02626884	IRENO	Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)	P2	completed	14	University of Cologne	Aug 2016
NCT02954406		A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma	P1	terminated	43	Millennium Pharmaceuticals, Inc.	Mar 2017
NCT03093831		Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma	P2	terminated	5	National Cancer Centre, Singapore	Jul 2016
NCT02406742	ENHANCE	A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	P1/P2	completed	47	Celgene	Jul 2015
NCT02301156	GENUINE	Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)	P3	completed	126	TG Therapeutics, Inc.	Jan 2015
NCT02743546	JNJ-64052781	Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma	P1	withdrawn	0	Janssen Research & Development, LLC	Jul 2016
NCT02689141	CLL2-BIO	Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)	P2	completed	66	German CLL Study Group	Feb 2016
NCT04043845		ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies	P1	withdrawn	0	Dana-Farber Cancer Institute	Feb 2020
NCT03572634		Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL	P1/P2	terminated	3	Sumitomo Pharma America, Inc.	Jun 2019
NCT02460276	PHILEMON	A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma	P2	completed	50	Lund University Hospital	Apr 2015
NCT03359460		Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome	P1	completed	4	University of California, Davis	Dec 2017
NCT02553941		Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome	P1	completed	21	Brian Jonas	May 2016
NCT02165397		Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia	P3	completed	181	Pharmacyclics LLC.	Jul 2014
NCT02575300		Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors	P2	completed	20	H. Lee Moffitt Cancer Center and Research Institute	Oct 2015
NCT02006485		Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies	P1	completed	160	TG Therapeutics, Inc.	Dec 2013
NCT02943473		Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients	P2	terminated	9	Icahn School of Medicine at Mount Sinai	May 2017
NCT02264574	CLL	A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)	P3	completed	229	Pharmacyclics LLC.	Oct 2014
NCT02912754		Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients	P1/P2	unknown	36	Sunnybrook Health Sciences Centre	Mar 2017
NCT02614508		Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	P1	terminated	1	Emory University	Jan 2016
NCT02759016		Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib	P1	completed	7	Boehringer Ingelheim	Jun 2016
NCT02874404		TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	P2	completed	13	University of Nebraska	Oct 2016
NCT02966730		Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy	Early P1	terminated	2	Memorial Sloan Kettering Cancer Center	Nov 2016
NCT03476655	CCL	Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India	—	completed	40	Johnson & Johnson Private Limited	Apr 2018
NCT02352558		A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies	P1	completed	15	Sumitomo Pharma America, Inc.	May 2015
NCT02780830	INHIBITOR	AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma	P1	withdrawn	0	AstraZeneca	Jun 2016
NCT02436668	RESOLVE	Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)	P3	completed	430	Pharmacyclics LLC.	May 2015
NCT01855750		A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma	P3	completed	838	Janssen Research & Development, LLC	Sep 2013
NCT01962792		Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma	P1/P2	completed	84	Pharmacyclics LLC.	Dec 2013
NCT02345863		Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients	P2	completed	66	German CLL Study Group	Jan 2015
NCT02973399		Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL	P1	terminated	5	Esanex Inc.	Feb 2017
NCT02801578	CLL	A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)	P2/P3	completed	11	M.D. Anderson Cancer Center	Jul 2016
NCT01611090		A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	P3	completed	578	Janssen Research & Development, LLC	Sep 2012
NCT02950220		Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	P1	completed	2	Kami Maddocks	Jan 2017
NCT02757040		Combination of Ibrutinib and As2O3 in the Treatment of CLL	P3	unknown	70	Peking University People's Hospital	Dec 2016
NCT03301207		A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy	P1	completed	25	Janssen Research & Development, LLC	Oct 2017
NCT03149315		Inhibition of Anaphylaxis by Ibrutinib	P2	completed	6	Ann & Robert H Lurie Children's Hospital of Chicago	Apr 2017
NCT02677948		Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)	P1/P2	withdrawn	0	University of Michigan Rogel Cancer Center	Oct 2016
NCT02902965		Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma	P2	completed	74	Pharmacyclics Switzerland GmbH	Sep 2016
NCT01578707	RESONATE™	A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	P3	completed	391	Pharmacyclics LLC.	Jun 2012
NCT02055924	BIBLOS	Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas	P1	terminated	85	The Lymphoma Academic Research Organisation	May 2014
NCT02582320		Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program	—	completed	264	Gruppo Italiano Malattie EMatologiche dell'Adulto	Mar 2016
NCT03145480		Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients	P2	terminated	3	Northwell Health	Jun 2017
NCT02556892	BTK	A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	P1	completed	8	Janssen Pharmaceutical K.K.	Jul 2015
NCT03469895	CABRI	Autoimmune Cytopenia and BcR Inhibitors	—	unknown	40	Institut Paoli-Calmettes	Jul 2017
NCT02914327		Safety and Activity of SNX-5422 Plus Ibrutinib in CLL	P1	withdrawn	0	Esanex Inc.	Feb 2017
NCT02548962		Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma	P1/P2	terminated	11	Pharmacyclics LLC.	Mar 2016
NCT02269085		Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma	P1	terminated	8	M.D. Anderson Cancer Center	Apr 2015
NCT02815059		Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone	P1	withdrawn	0	University of Utah	Sep 2016
NCT02272686	SCT	Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma	P2	terminated	1	M.D. Anderson Cancer Center	Jun 2016
NCT02401048		A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas	P1/P2	completed	61	Pharmacyclics LLC.	May 2015
NCT01980654		Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma	P2	completed	80	Pharmacyclics LLC.	Dec 2013
NCT02635074		Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	P1	terminated	2	Steven E. Coutre	Nov 2016
NCT01980628		Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma	P2	completed	63	Pharmacyclics LLC.	Dec 2013
NCT02195869		Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease	P1/P2	completed	45	Pharmacyclics LLC.	Jul 2014
NCT02403271		A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors	P1/P2	completed	124	Pharmacyclics LLC.	Mar 2015
NCT02142049		Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma	P1/P2	completed	35	Pharmacyclics LLC.	May 2014
NCT01973387		A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma	P3	completed	160	Janssen Research & Development, LLC	Oct 2013
NCT02200848	CLL	Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)	P1	terminated	5	Georgetown University	Apr 2014
NCT02415608		Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis	P2	terminated	4	Jason Robert Gotlib	Mar 2015
NCT02219737		Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma	P1	completed	26	National Cancer Institute (NCI)	Sep 2014
NCT02351037		Study of Ibrutinib in Subjects With Acute Myeloid Leukemia	P2	terminated	36	Pharmacyclics LLC.	Feb 2015
NCT02670317	FIL-GALILEO	Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.	P2	terminated	1	Fondazione Italiana Linfomi - ETS	Sep 2016
NCT02950038	NSCLC	Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)	P2	withdrawn	0	M.D. Anderson Cancer Center	Dec 2016
NCT02169180	BTK	Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma	P2	completed	16	Janssen Pharmaceutical K.K.	Aug 2014
NCT01646021		Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy	P3	completed	280	Janssen Research & Development, LLC	Dec 2012
NCT02877225		Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule	P1	completed	103	Janssen Research & Development, LLC	Aug 2016
NCT02841150		Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules	P1	completed	102	Janssen Research & Development, LLC	Jun 2016
NCT02381080	CYP	Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy	P1	completed	26	Janssen Research & Development, LLC	May 2015
NCT02735876		A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma	P3	withdrawn	0	Acerta Pharma BV	May 2016
NCT01779791		A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma	P2	completed	110	Janssen Research & Development, LLC	Apr 2013
NCT01744691	CLL	A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion	P2	completed	145	Pharmacyclics LLC.	Jan 2013
NCT02662296		Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant	P2	withdrawn	0	Fred Hutchinson Cancer Center	Mar 2016
NCT02638116		A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults	P1	completed	20	Janssen Research & Development, LLC	Jan 2016
NCT02013128		Ublituximab + Ibrutinib in Select B-cell Malignancies	P1/P2	completed	66	TG Therapeutics, Inc.	Jan 2014
NCT02390609		A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults	P1	completed	40	Janssen Research & Development, LLC	Mar 2015
NCT02129062		Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia	P2	terminated	3	National Cancer Institute (NCI)	Apr 2014
NCT02109224		Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection	P1	terminated	72	National Cancer Institute (NCI)	Sep 2014
NCT02271438		A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants	P1	completed	28	Janssen Research & Development, LLC	Oct 2014
NCT01722487		Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL	P3	completed	269	Pharmacyclics LLC.	Mar 2013
NCT01599949		A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy	P2	completed	120	Janssen Research & Development, LLC	Aug 2012
NCT02437019	EAP	Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)	—	approved for marketing	0	Janssen-Cilag Farmaceutica Ltda.	—
NCT01325701		Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma	P2	completed	78	Pharmacyclics LLC.	May 2011
NCT01833039		An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma	—	approved for marketing	0	Janssen Biotech, Inc.	—
NCT01674322		A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants	P1	completed	6	Janssen Research & Development, LLC	Aug 2012
NCT01626651		A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants	P1	completed	21	Janssen Research & Development, LLC	Jun 2012

Ibrutinib clinical trials: frequently asked questions

How many Ibrutinib clinical trials are there?: 352 Ibrutinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 36 are actively recruiting participants. 152 are marked completed.
Are Ibrutinib clinical trials recruiting in 2026?: Yes — 36 Ibrutinib trials are actively recruiting in 2026, with 557 U.S. sites across 44 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Ibrutinib being studied for?: Ibrutinib is being studied for Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Recurrent Small Lymphocytic Lymphoma and 407 more. The trials are grouped by indication on this page.
What phase is Ibrutinib in?: Ibrutinib clinical trials span 4 Phase 4, 53 Phase 3, 148 Phase 2, 75 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Ibrutinib clinical trials?: The lead sponsor across the most Ibrutinib trials is Janssen Research & Development, LLC, with 139 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Ibrutinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 16, 2026.

Related pages on Hipa.ai:

Ibrutinib overview Ibrutinib evidence & publications